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Preface 
This thesis presents the results of my work at Otto Bock HealthCare GmbH 
Duderstadt and the Fondazione Ospedale San Camillo Venedig-Lido, within the 
MYOSENS project funded by the European Commission’s Marie-Curie actions, 
Industrial Academia Partnerships and Pathways Program (IAPP). Grant No. 286208. 
Project duration: April 1st 2012 – April 1st.2016. 
All studies involving human subjects were approved by the Institutional Review 
Board of Fondazione Ospedale San Camillo and informed written consent was 
obtained by all participants at the time of enrolment. 
All sections of this thesis are original and written by me. Only sections 3.1 and 3.2 
have been adapted from one manuscript I submitted to BioMed Central for 
consideration [1] and one published conference paper in IEEE [2], respectively. All 
graphics in this manuscript are original and created solely by myself.  
Hereby, I declare that I have written this thesis independently and with no other aids 
and sources than quoted. 
 
 





The majority of individuals with stroke experience problems with the upper extremity, 
of which paresis is most common. The use of robotics in upper limb therapy is 
increasingly popular, as it can deliver intensive and functional arm rehabilitation. This 
thesis describes the development of a functional and robust myoelectric control 
interface for the pneumatic shoulder RehaARM robot1, using electromyographic 
biofeedback, and the design of a therapeutic approach for shoulder treatment after 
stroke with this technology. The therapeutic approach has been evaluated in a phase 
II clinical trial2.  
The developed interface goes beyond the state-of-the-art technologies for upper limb 
therapy in clinical research because it is capable of online myoelectric control of the 
robot with three degrees of freedom (DoF), supporting shoulder movements. 
Myoelectric control has been applied only in systems providing 1-DoF movements 
for the elbow or wrist. The developed RehaARM system surpasses previously 
developed systems in the number of actuated DoF. More importantly, the developed 
myoelectric control interface is transferable to other active-assistive robots for upper 
limb therapy. The thesis also describes novel neurophysiological measurements for 
evaluating the effectiveness of the treatment with the RehaARM system and 
presents their correlation with the most commonly used clinical impairment and 
activity upper limb scales.  
                                            
 
1 FerRobotics Compliant Robot Technology GmbH, AT 
2 Trial registration: ClinicalTrials.gov, Identifier: NCT02321254 and see section 3.3.2.1 
III 
 
The resulting system has been tested on both healthy volunteers and stroke patients 
and has been compared with the commercially used torque (force) control. Our 
experimental studies confirm the benefit of the developed myoelectric control 
interface for the RehaARM robot. RehaARM with myoelectric control achieved 
equally desirable effects on muscle activation, namely synergistic activation (muscle 
recruitment) and modulation of activation levels as torque (force) control. 
Results showed that severely, moderately and mildly impaired patients were able to 
successfully control the RehaARM system with myoelectric control with greater ease 
than torque control for task-specific shoulder training. Myoelectric control was used 
by severely impaired patients who have very low residual voluntary forces which are 
rarely detectable by commercially available robots. For all patients, there was a 
monotonic increase in the movement completion rate over multiple sessions that 
showed improvement in voluntary control. The therapeutic approach with the 
RehaARM myoelectric interface significantly improved both motor control (FMA-UE) 
and activity (FIM) scores. The difference between effects of robotic and conventional 
therapy alone – comparable dose and dosage – was not significant.  This is in 
agreement with the evidence found in the scientific literature. Based on the FMA-UE 
scores, the sample sizes needed to determine the effectiveness of the treatment 
were similar for conventional therapy (n = 27, p<0.05; power = 0.8) and RehaARM 
therapy (n = 28, p<0.05; power = 0.8).  The results of clinical and neurophysiological 
assessments in this clinical trial can be used to compare this therapy’s effectiveness 
with future randomized clinical trials of upper limb therapies in terms of effect size of 
the treatment. Based on the results, the use of the RehaARM robot is continued and 
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ADLs Activities of daily living 
ABD  Abduction 
ADD Adduction 
CIMT Constraint induced movement therapy 
CVT Conventional therapy group 
CT Computer tomography 
DoF Degrees of freedom 
EMG Electromyography 
EMG-S Similarity between the muscle activation of healthy subjects 




FMA Fugl-Meyer Assessment of motor recovery after stroke 
FMA-UE Upper extremity section of the Fugl-Meyer Assessment of motor 
recovery after stroke 
FIM Functional Independence Measurement 
ICA Internal carotid artery 
ICH Intracerebral hemmorhage 
IE Internal/external rotation 
MAS Modified Ashworth Scale 
MCA Middle cerebral artery 
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MDC Minimum detectable change 
MCID Minimally clinically important difference 
MRI Magnetic resonance imaging 
Motor-FIM Motor portion of the Functional Independence Measurement 
MVC Maximum voluntary contraction 
NHPT Nine-Hole Pegboard Test 
NMES  Neuromuscular electrical stimulation 
NMF Non-matrix factorization 
PCA Posterior cerebral artery 
PACI Partial anterior cerebral Infarct 
POCI Posterior cerebral infarct 
RPS Reaching Performance Scale 
ROM Ranges of motion 
SAH Subarachnoid hemmorhage 
SMI Somato-sensory integration 
SRI Stroke to rehabilitation interval 
TACI Total anterior circulation infarct 
TORQUE-S Similarity between the muscle activation of healthy subjects 
(median) and the muscle activation of stroke patients  when using 
torque control 
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1.1 State of the art 
Stroke is worldwide a leading cause of disability [3]. The corresponding incidence 
rates3 standardized to the world population are 71 (95% CI 55 to 88) for ischemic 
stroke (cerebral infarction), 16 (95% CI 8 to 23) for intracerebral hemorrhage, 6 (95% 
CI 1 to 11) for subarachnoid hemorrhage, and 7 (95% CI 2 to 12) for undetermined 
stroke [4]. 
Most stroke individuals survive, albeit often with severe impairments, such as 
sensory and motor hemiparesis, spasticity, and lack of coordination in the muscle 
activation of the contralateral side of the body. The most common post-stroke 
problem is paresis of the upper extremities. Upper limb paresis is found in more than 
two-thirds of all patients at hospital admission [5], [6]. After a six month period, while 
performing activities of daily living (ADLs) the upper limb remains non-functional in 
up to 66% of all stroke patients and only 5% to 20% demonstrate complete functional 
recovery [7]. Therefore, the most disabling of all residual impairments is to remain 
without function in ADLs. This can lead to loss of independence in ADLs and of 
important occupational activities (e.g. work, driving). Furthermore, it can even result 
in institutionalization and the development of neuropsychological disorders like 
depression and anxiety [8]. 
Effective post-stroke upper limb rehabilitation has not yet been reached. In light of 
this limited success of traditional rehabilitation programs in recovering upper limb 
                                            
 
3 Rates per 100.000 population per year for first-ever-in-a-life-time stroke. Age and sex adjusted to the 
world population of Segi. Statistics based on a study done in Melbourne, Australia (1996–1997) 
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function after stroke, research has focused on innovative motor recovery therapeutic 
approaches. It has been shown that for stroke survivors highly repetitive, task-
specific upper limb training facilitates cortical plasticity in the brain and is effective for 
improving motor abilities and functional activity performance of the upper limb [9]–
[12]. In other words, task-specific training or functional task practice is based on the 
premise that practice of an action results in enhanced performance of that action by 
focusing on learning or relearning motor skills (neuroplasticity) [13], [14]. A number 
of techniques have been proposed to facilitate the delivery of or include task-specific 
training, including constraint-induced movement therapy (CIMT), neuromuscular 
electrical stimulation (NMES), virtual reality and robot-aided rehabilitation [8].  
CIMT can be beneficial for eligible stroke survivors [8]. According to an in 2015 
updated Cochrane review, CIMT appeared to be more effective at improving arm 
movement than active physiotherapy treatments or no treatment. However, the 
quality of the evidence is limited by the small numbers of study participants and poor 
reporting of study characteristics [15]. NMES can be effective for individuals with 
minimal voluntary movement within the first few months after stroke or for individuals 
with shoulder subluxation. NMES can be used in combination with task-specific 
training, especially for the wrist and hand muscles [8].  Virtual reality and gaming are 
reasonable treatments to engage individuals with stroke and increase the amount of 
upper limb movement practice because it can be enjoyable for patients. However, 
virtual reality without arm support can be used solely with patients with moderate to 
mild impairment who have some active control of the upper limb and can overcome 
gravity by lifting the arm. An in 2015 updated Cochrane review found evidence that 
the use of virtual reality and interactive video gaming may be effective in improving 
upper limb function and ADL function when used in combination with conventional 
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therapy (to increase overall therapy time) or compared with the same dose of 
conventional therapy. These results should be interpreted cautiously as the studies 
had small numbers of participants [16]. 
Other therapeutic modalities like mental imagery and strengthening exercises are 
also reasonable to consider in combination with functional task practice. The 
following therapeutic modalities have been the target of multiple studies, but have 
not yet shown consistent effectiveness in post-stroke upper limb motor recovery. 
These modalities are: noninvasive brain stimulation (transcranial magnetic 
stimulation, TMS, or transcranial direct current stimulation, tDCS), somato-sensory 
stimulation combined with upper limb exercise therapy, and interventions focusing on 
motor apraxia and manual therapy approaches such as stretching, passive exercise, 
and mobilization. These modalities are standard treatments for more severely 
impaired individuals used to prevent contractures and to manage spasticity [8].  
Robotic devices are particularly interesting because they can provide exercise 
therapies in accurate, reproducible and high dosages. It can help patients regain 
their arm function by supporting the patients’ movement with fun exercise games in 
virtual reality that motivate them towards a more active effort and greater 
involvement. Robotic therapy can be an effective treatment for providing more 
intensive therapy to individuals with moderate to severe upper limb paresis. 
Numerous studies have shown its positive effect. A Cochrane review updated in 
2015 found that upper limb robotic therapy provided benefits with regard to ADLs 
and arm function. However, studies comparing dose-matched exercise between 
robotic and conventional therapy have shown minimal or no differences in the 
efficacy of these two treatments [5], [8]. Robotic-assisted therapy will not give better 
results than human delivery movement therapy if all variables are matched [17].  
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Robotic therapy in combination with conventional therapy is becoming increasingly 
common for treatment of the upper limb. Robotic devices have the potential to 
complement traditional neurological rehabilitation requiring greater investments of 
resources and time. Recovery after stroke varies markedly. Certain people can 
restore their upper limb function relatively quickly; for others recovery can take a long 
time or can even be a lifelong process [18]. There is a lack of professionals and the 
costs for adequately covering all patients who need inpatient and outpatient 
rehabilitation are high. The higher intensive training with robotic devices can be 
justified considering its cost-effectiveness.  
Therapy is generally provided on one to one ratio of therapist to patient. Robotic-
assisted therapy may potentially facilitate therapy with a lower ratio, without 
negatively affecting efficacy. Clinical research should employ well-designed 
randomized clinical trials to test whether robotic-assisted therapy – with a lower than 
one ratio of therapists to patients – in combination with one-on-one conventional 
therapy has a higher efficacy and greater cost-effectiveness compared to one-on-
one conventional therapy only. This could be one therapist providing therapy to two4 
or more patients [19], or for example, two therapists per three or more patients. This 
is already happening in rehabilitation clinics4,5 and will become more popular in a 
near future. This may contribute to reducing healthcare costs, or to increasing the 
amount of therapy provided. Future research should examine the feasibility and 
impact on efficacy of such settings taking on account impairment level and patient’s 
state. 
                                            
 
4 For example, at St. Mauritius Therapieklinik, Meerbusch, Deutschland one therapist treats two 
patients (1:2 ratio) with similar impairments 
5 For example, Loius Stokes Cleveland Department of Veteran Affairs (VA) Medical Center, Medical 
Research, Cleveland, OH 
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In recent years, the compliant behavior of rehabilitation robots has become a 
relevant factor in their further development in order to ensure safe interaction with 
the patient, emulate the properties of human limbs, and provide human-like contact 
[20]. The compliant operation can be implemented in two ways: it can be actively 
simulated using electric drives [21] (e.g. impedance control) or it can be an inherent 
feature of the robot’s structural/mechanical design, as for example, when using 
pneumatic actuators [22].  
There are several robots driven by electric motors that implement active compliance 
for upper limbs training and/or gravity compensation. For example, InMotion ARM™ 
(clinical version of the MIT-Manus) is a commercial 2-DoF robot manipulator that 
assists shoulder and elbow movement by guiding the patient’s hand in the horizontal 
plane [23]. The Assisted rehabilitation and measurement guide (ARM-GUIDE) 
supports shoulder and elbow movements in different directions. The user’s hand is 
moved along a linear rail similar to a trombone slide [24]. The Mirror Image 
Movement Enabler (MIME) is a 6-DoF robot manipulator for the training of the elbow 
and shoulder [25]. The ARMin, and its commercially available version ArmeoPower, 
support the motion of shoulder, elbow, and wrist joints (6 DoF), covering a full 3-D 
workspace [26]. 
Pneumatic robots are increasing in popularity because of the high power-to-weight 
ratio, low cost and direct drive capabilities of pneumatic actuators [27]. RUPERT is a 
5-DoF robot for assisted shoulder elevation, humeral external rotation, elbow 
extension, forearm supination and wrist/hand extension [28]. The Salford 
rehabilitation exoskeleton (SRE) is a wearable 7-DoF gravity compensating 
exoskeleton, supporting the shoulder (3 DoF), elbow (2 DoF) and wrist movements 
(2 DoF) [20]. The iPAM (Intelligent Pneumatic Arm Movement) consists of two 
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identical robot arms: the distal orthosis controls the movement of the patient’s 
forearm, while the proximal orthosis – attached at the mid-point of the upper arm – 
controls the proximal arm movement. With a total of six active DoF, it can support 
the movements of the shoulder (5 DoF) and elbow (1 DoF) joints, providing 
assistance during, for example, reach-retrieve, pick-and-place and hand-to-mouth 
movements [27]. The PNEU-WREX is a 4-DoF, gravity compensating robot assisting 
elbow flexion/extension, shoulder horizontal abduction/adduction, flexion/extension, 
and forward-backward translation. The system monitors the patient's behavior and 
constructs a real-time computer model of the patient’s level of impairment. The 
model is then used to provide feedforward assistance using a compliant position 
controller [29]. 
Commercially available rehabilitation robots for treatment of the upper limb use 
control schemes like force, torque and impedance control. The most common control 
paradigm is the impedance control which has been proven adequate for high-ratio 
transmitting systems. In this scheme, the robot reads information from the human-
machine interaction through contact forces and uses it to support the limb in the 
rehabilitation tasks. It has been applied successfully in numerous robot applications 
that involve human-motor interaction. This control scheme combined with complex 
tasks in a 3-D space has proven to be successful for use with less severely impaired 
patients who have some degree of control to break out of their stroke pattern and 
some residual force to interact with the robot. The stroke patterns for the arm are:  i) 
the arm flexion pattern that is the most common among stroke survivors – arm 
resting against the body, elbow flexed with forearm across the abdomen and hand 
closed – or ii) the arm extension pattern – elbow, wrist and fingers rigidly straight. 
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The most well-studied robotic devices (e.g. ARMin, MIME, MIT-MANUS, [30]) use 
impedance control or measure residual volitional force to activate the robot [23], [31]. 
From my experience on the field of robotic-assisted technologies for upper limb 
therapy, the drawback of some commercially available active-assistive robots is the 
lack of sensitivity and transparency, and therefore, the responsiveness of these 
systems (force sensors cannot read the intended movement) to the scarce residual 
force of the paretic upper limb of stroke survivors. The system’s sensitivity is the 
minimum magnitude of an input signal required to produce a specified output signal 
having a specified signal-to-noise ratio, or other specified criteria. Transparency 
refers to apparent robot dynamics that the user feels in “free space” motion, when 
the user moves the robot. The user should not feel these apparent dynamics. Forces 
that need to be overcome when moving a robot are inertia, gravity, friction, and 
Coriolis and centrifugal forces. The sensitivity and transparency of the system are 
determined by the sensors (e.g. force sensors in force/torque control) and the 
control. A lightweight construction and/or compliant actuation reduce these forces, 
but this reduction is limited [32]. The users, especially the more severely impaired 
patients, feel this residual seeming inertia, cannot often overcome it and cannot 
activate the robot. This limitation applies to closed-loop impedance and force/torque 
controlled electrical robots [32], [33] and pneumatic robots. Consequently, severely 
impaired patients are often assigned to conventional therapy only because they 
cannot activate the robot. High sensitivity and transparency is a prerequisite to 
keeping the patient engaged in the task and permitting him to observe his successful 
and unsuccessful attempts at moving. 
Another drawback is the high complexity of tasks. The tasks and games are often 
too complex for the lacking sensitivity and transparency of the robot, and the few 
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available control signals from the paretic upper limb. Even though some systems can 
be sensitive to detecting the movement of some joints, the patient (particularly those 
more severely impaired) is often overwhelmed and cannot execute complex tasks 
involving the activation of more than one DoF.  
Finally, there is a mismatch between the few control signals obtained from the 
subject’s attempt of movement and the task complexity. Therefore, some of the 
systems arbitrarily decide the path of a complex task based on few control signals 
while there are usually multiple paths for executing a task. Especially for gaming in a 
3-D space, those systems’ schemes attached to a predefined trajectory are impeding 
the subject’s freedom of movement. As the complexity of the task increases, the 
appropriateness of a predefined trajectory decreases. As a result, the subject neither 
understands the task nor acts as the initiator of his movements. This can be 
confusing for patients (especially for more severely impaired patients) given their 
cognitive disabilities after stroke. And therefore learning is inhibited and frustration 
arises. 
The only extensive study on the feasibility of using the 7-DoF ARMin robot with 
patients with severe-to-moderate impairments has been published in Lancet 
Neurology [26]. The results of this multicenter, randomized clinical trial showed the 
practicability of the ARMin robot for upper limb therapy and agreed with previous 
available evidence: upper limb training with a robotic system is safe and improves 
motor function and abilities of ADLs [34]. However, force sensors and closed-loop 
force/impedance control may not always be enough to detect and use the residual 
voluntary force of severely impaired patients for controlling the robot. Other 
techniques, like myoelectric control, can complement the readings from the force 
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sensors and the control system to help better interpret and use the subject’s 
intention of movement [18]. 
There are only few active robotic rehabilitation systems integrating EMG signals into 
the control loop. In two studies [35], [36], EMG signals were used to control 
exoskeleton robots, by estimating the joint torque generated by the subject according 
to the EMG signals, and then computing the required assistive torque. In another 
study [30], surface EMG was used to detect the intention of the user to move the 
elbow and then, when necessary, provide assistance using a powered elbow 
orthosis (Myomo, Inc., Boston, MA, USA). Other researchers [37], proposed an 
active assistive robot with myoelectric control in a closed loop for elbow rehabilitation 
using a tracking task, and a similar concept was later applied to the wrist [38]. They 
demonstrated better clinical outcomes for the myoelectric (also EMG-driven) robot of 
the wrist compared to passive (open loop) robot training. Single DoF exercises at the 
elbow and wrist improved the muscle coordination and reduced spasticity. These 
results indicate the potential for employing EMG signals in closed loop to advance 
robotic upper limb therapy. 
1.2 Motivation and objective 
Combining a high sensitivity, transparency and high force production required to 
move the paretic limb all in one machine is often difficult to accomplish. This difficulty 
increases along with increases in complexity of the robot's geometry. Therefore, for 
this PhD project, the RehaARM robot was enhanced with myoelectric control in order 
to increase the system’s sensitivity and transparency and be able to detect the 
individual's intention of movement by measuring residual muscle activity of the 
paretic upper limb. The enhanced RehaArm (FerRobotics Compliant Robot 
Technology GmbH, AT) is a compliant robotic arm exoskeleton with 3 DoF for 
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shoulder rehabilitation. It mechanically supports the upper arm, lower arm and hand 
while assisting with shoulder movements. The shoulder joint is actuated while the 
elbow and wrist are immobilized to attenuate their activity and focus the therapy on 
the shoulder. Hence, RehaArm with the developed myoelectric interface can be use 
in early stage shoulder treatment for passive and active single joint shoulder 
mobilization. The robot implements a soft and slow moving mechanism for a gentle 
interaction with the subject. This novel system enables performing exercises with the 
robot in a closed loop, by providing visual feedback on task progress and muscle 
activity, in order to have a complete sensorimotor integration, wherein the subject is 
also actively engaged and motivated to initiate and achieve the tasks. To the best of 
my knowledge, this is the first pneumatically actuated rehabilitation robot for the 
shoulder, controlled in closed-loop using myoelectric control and visual feedback. 
This implementation, together with the description of the RehaARM robot, is outlined 
in sections 2.1, 2.2 and 3.1.  
Furthermore, this project assessed whether myoelectric control is more practicable 
than torque control of the RehaARM robot in a clinical setting (section 3.2). Finally, a 
phase II clinical trial with the myoelectric controlled RehaARM robot was designed. 
This trial is registered in ClinicalTrials.gov (identifier: NCT02321254), section 3.3. 
The aim of this clinical trial was to assess the clinical effectiveness of the robotic-
assisted upper limb therapy with myoelectric control (in terms of effect size) and to 
determine the feasibility of incorporating this type of therapy in daily rehabilitation 
programs. Moreover, the influence of the severity of motor impairment, stroke type 
and the Stroke to Rehabilitation Interval (SRI) – meaning the distance in time 
between stroke onset and the start of the rehabilitation treatment – on motor and 
functional outcomes were also investigated. Finally, I investigated the acceptance of 
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this intervention by patients and therapists. The recruiting has been completed and 
the results are being reviewed by ClinicalTrials.gov for closing the trial. 
 
The objective of this PhD project can be summarized as follows: 
 
Development of a novel, robust and functional myoelectric controlled robotic 
system for upper limb therapy after stroke, and design and execution of a 
clinical trial to test the efficacy of the therapy with clinical, kinematic and novel 




The rehabilitation technologies available for the treatment of upper motor limb 
impairment after stroke of more severely impaired patients are limited. Therefore, the 
RehaARM robot and the therapeutic concept of the novel robot-assisted therapy in 
closed-loop with myoelectric control were implemented and are presented in the 
following.  
Section 2.1 introduces the RehaARM Robot, a robot specifically developed for 
shoulder rehabilitation [1]. The mechanical structure and operation of the RehaARM 
robot are explained in detail.  
Section 2.2 presents the online closed-loop command interface with EMG-
thresholding which was designed following SMI principles. In this section, the 
mechanical adjustments, the software calibration of the system for each individual 
setting and the closed-control loop with myoelectric and torque control are 
presented.  
Section 2.3 presents the clinical, kinematic and neurophysiological assessments 
used in the experimental studies (section 3). 
2.1 RehaARM robot 
The mechanical structure of the exoskeleton robot (Figure 1) resembles the human 
arm anatomy, and the robot’s links correspond to human joints. The structure can be 
adjusted for each subject anthropometry. The humeral and forearm length can be set 
using mechanical sliders while the adjustment of the shoulder is electrical and 
mechanical. Electrically, the height of the chair can be changed along the sagittal 
plane in order to secure the individual shoulder girdle elevation. The transverse chair 
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displacement can be modified in order to secure the individual protraction/retraction 
position of the scapulothoracic joint. Mechanically, the lateral alignment of the 
scapula can be set by displacing the chair along the coronal plane (Figure 1(d)). In 
this way, the shoulder joint is centered to the robot axes of rotation, which should 
cross in the center of the shoulder joint. This can be verified using laser pointers 
embedded in the robot structure (Figure 1(a-c)).  
The elbow is positioned at 90° of flexion and the wrist in neutral position (i.e., 0° 
flexion/extension and 0° pronation/supination). The lengths of the links L1, L2 and L3 
are 67 cm, 53 cm and between 10 to 20 cm (adjustable), respectively (Figure 1(a, 
d)). The system provides single arm therapy, but it can be reconfigured easily for the 
 
Figure 1: Model of the RehaArm robot. a) Right arm exoskeleton and its three rotational axes 
for DoF1, DoF2 and DoF3, corresponding to horizontal adduction/abduction (HORZ ADD/ABD), 
adduction/abduction (ADD/ABD) and flexion/extension (FE), and internal/external rotation (IE), 
respectively (c). The robot arm is connected to a chair (b) on which the subject sits 
comfortably, entirely supporting the arm on the exoskeleton while executing the movements 
(d). The surface EMG electrodes are mounted on the shoulder muscles to implement EMG-
driven control.  
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left or right arm to treat patients with brain lesions in the right and left hemispheres.  
In addition to subject anthropometry, the robot can be calibrated to the arm 
dynamics. To this aim, the robot measures the weight of the arm at a predefined 
position (shoulder horizontally abducted and abducted according to the maximum of 
the subject’s passive ROM). The arm model is then used to estimate the 
gravitational joint moments in an arbitrary position and, based on that, the control 
signals for the actuators are computed in order to implement feedforward gravity 
compensation. 
RehaArm is able to replicate the principal movements of the shoulder with a proper 
configuration of its 3 DoF. The first DoF implements a horizontal adduction/abduction 
(HORZ ADD/ABD), i.e., a movement along the transverse plane. The second DoF 
implements an adduction/abduction (ADD/ABD) when the exoskeleton arm is 
horizontally abducted, i.e., a movement along the coronal plane, and a 
flexion/extension (FE) when the arm exoskeleton is adducted more than 40°, i.e., a 
movement along the sagittal plane. The third DoF (IE) reproduces the 
internal/external rotation (IE) (Figure 1(c, d)).  
The maximum movement speed of the robot is 5°/s and the maximum ranges of 
motion (ROM) for HORZ ADD/ABD (DoF1), ADD/ABD and FE (DoF2), and IE 
(DoF3) are 106°, 146° and 160°, respectively. To accommodate the limited motion of 
the patient’s shoulder, the therapist can customize the active ROM of each DoF by 
setting the minimum and maximum angle positions via software (see section 2.2). 
The DoF are driven by using antagonistic pairs of pneumatic muscle actuators (Fluid 
Muscle DMSP, Festo) [39], i.e., six artificial muscles in total. Due to the 
compressibility of air, the artificial muscles are inherently compliant and they can 
therefore absorb or at least reduce the contact forces ensuring safety while 
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interacting with the patient. If the subject moves the robot from the current reference 
position, the robot generates restorative force. This force comprises a constant 
instantaneous reaction, which is proportional to the deviation, and a gradually 
increasing component (ramp up). The latter can increase only until the total force 
reaches the maximum value, which is a settable parameter. 
2.2 Online Closed-Loop Command Interface with EMG-Thresholding 
A user-friendly control interface was developed for the RehaArm for the execution of 
closed-loop, patient-driven experimental protocols. The system includes a 
multichannel EMG amplifier (EMGUSB2, OTbioelettronica, Torino, IT), a control PC 
and a standard 22” computer monitor (Figure 2(a)). The robot and the control PC 
communicated via three unidirectional TCP/IP connections (Figure 2(b)) to set the 
robot configuration parameters (e.g. maximum torques, maximum ROM), send the 
desired trajectory (e.g. DoF angles) and receive sensor data for each DoF (e.g. DoF 
angles and torques) at a sampling frequency of 100 Hz.  
The visual feedback modalities for the different experimental protocols were 
displayed on the monitor and are explained in section 2.2.5 (Figure 2(c1-2)). The 
robot was controlled in position mode, i.e., the control PC sent a desired position 
(DoF angles) to the robot, which then exerted forces to drive the subject limb 
towards that position. The closed-loop control framework also implemented the 
teaching mode, in which the robot produced zero torques allowing the experimenter 
to move it freely through the workspace (while the subject was seated in the robot). 
The trajectory was recorded and could be replayed or analyzed in order to set the 
range of motion for each DoF, as explained in section 3.1.2.2. 
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2.2.1 Subject Positioning 
The subject was seated comfortably on the chair (Figure 1(b)) and his/her upper limb 
was strapped to the robotic arm with a soft harness just below the elbow and around 
the wrist (Figure 1(d)). The link lengths were adjusted according to the subject 
anthropometry. The experimenter (physiotherapist) took special care to position the 
humerus correctly, maintaining the parallel alignment of both shoulders before 
movement. Optimal positioning was necessary in order to activate the muscles 
responsible for the stability of the shoulder (stability before mobility [40]). Afterwards, 
 
Figure 2: Closed-loop control framework developed for RehaArm. (a) A control PC was 
connected to an EMG amplifier, the robot and a computer monitor. (b) Three unidirectional 
TCP/IP connections were used to configure the robot, send the desired position, and receive 
the sensor data. (c) Visual feedback to the subject displayed on the monitor placed in front of 
the subject for the single-DoF task (HORZ ADD/ABD) (c1) and for the EIGHT task, a 
simultaneous combination of two single DoF tasks: HORZ ADD/ABD and FE (c2). The grey 
shaded area in c1 was displayed in the tasks with EMG-driven control (section 2.2.5). See text 
for explanation.  
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during the experiment, the physiotherapist continuously controlled the subject’s arm 
and trunk movements in order to avoid compensatory mechanisms. 
2.2.2 EMG Recording and Processing 
For the tasks execution, the surface EMG data was recorded from six shoulder 
muscles (the triggering muscles). We selected the prime movers of the shoulder joint 
(pectoralis major, anterior, middle and posterior deltoids) and the rotator cuff 
muscles (infraspinatus and teres major). The rotator cuff muscles were included 
since they are the key muscles involved in the glenohumeral stability, dynamic 
stability and controlled mobility of the shoulder complex. It is known that the lack of 
glenohumeral stability causes shoulder subluxation, the lack of dynamic stability 
leads to a non-functional shoulder posture and the lack of controlled mobility 
impedes smooth movements [40], [41]. 
For the neurophysiological assessments, the surface EMG data was recorded from 
sixteen shoulder muscles, including the triggering muscles. The recorded muscles 
included triceps brachii, lateral (channel 1) and medial heads (channel 2); biceps 
brachii, short (channel 3) and long heads (channel 4); deltoid, anterior (channel 5), 
medial (channel 6), and posterior parts (channel 7); superior trapezius (channel 8); 
rhomboid major (channel 9); brachioradialis (channel 10); supinator (channel 11); 
brachialis (channel 12); pronator teres (channel 13); pectoralis major, calvicular head 
(channel 14); infraspinatus (channel 15); and teres major (channel 16). We recorded 
16 EMG channels in order to assess the muscle activation of the upper arm [42]. 
The bipolar electrodes were placed over these muscles following the guidelines of 
the Surface Electromyography for the Non-Invasive Assessment of Muscles 
European Community project (SENIAM, [43]). The acquired EMG signals were 
amplified with a gain of 1000, band-pass filtered (8th order Bessel filter, bandwidth 
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10–500 Hz), sampled at 2048 Hz and A/D converted with a resolution of 12 bits 
using a multichannel EMG amplifier connected via USB to the control PC. A 
reference electrode was placed around the wrist of the right arm. The acquired 
digitized EMG signals were high-pass filtered (5th order Butterworth filter, cutoff 20 
Hz) to remove motion artifacts. A band-stop filter (5th order Butterworth filter) was 
applied to remove the power line 50 Hz noise. The EMG signals were rectified and 
low-pass filtered (5th order Butterworth filter, cutoff 6 Hz) to compute a linear 
envelope for each channel for the myoelectric control. For the neurophysiological 
assessments, the unrectified EMG-signals were further processed offline in order to 
obtain the neurophysiological measures (see section 2.3.3).  
In the following, recording refers to the acquisition of EMG signals for online control 
and offline analysis. For study 1, the surface EMG data from the triggering muscles 
of stroke patients (n=12) were recorded during each daily session (four sessions in 
total for study 1). Surface EMG data was also recorded from sixteen shoulder 
muscles (including the triggering muscles) of healthy volunteers during the first only 
session (n=10) (see section 3.1). For study 2, the surface EMG data from the 
triggering muscles of stroke patients (n=23) were recorded during each daily session 
(four sessions in total for study 2) and from sixteen shoulder muscles (including the 
triggering muscles) in session 4 for a subgroup of stroke patients (n=20) (see section 
3.2). For study 3, the surface EMG data was recorded from the triggering muscles of 
stroke patients (n=20) during sessions 2 to 16 and from sixteen shoulder muscles in 
the session 1 and 17 (seventeenth sessions in total for study 3, see section 3.3). 
2.2.3 Myoelectric Control with Thresholding 
The EMG-driven control was a threshold-based algorithm. To trigger the assistance 
of the robot, the subject had to activate the selected muscle (task dependent) to 
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produce above-threshold EMG activity. Visual feedback about the robot position 
(shoulder angle) and the level of EMG activity of the triggering muscle was shown to 
the subject (see section 2.2.5). The robot assisted the patient to complete the task 
only if the EMG activity of the respective muscle exceeded the required threshold. 
For online myoelectric control, we obtained the momentary level of muscle activation 
(𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 (𝑚𝑚)) which was the mean of the linear envelope for each channel computed 
 
Figure 3: Diagram of the EMG-driven (both switches in position (1)) and torque control (both 
switches in position (2)) algorithms for the robot’s active assistance in the engineering studies 
1 and 2 (see sections 3.1.2.2 and 3.2) and the clinical trial (study 3, section 3.3). In myoelectric 
control, the robot assisted the patient to progressively complete the task if the momentary 
level of muscle activation (𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨 (𝑨𝑨)) of the respective muscle at the moment 𝒕𝒕𝑨𝑨  for the chosen 
task exceeded the required muscle threshold (𝑻𝑻𝑻𝑻𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨 (𝑨𝑨)) and the patient followed the desired 
trajectory. In torque control, the robot assisted the patient to progressively complete the task if 
the momentary torque level (𝑻𝑻𝑻𝑻(𝑨𝑨)) at the moment 𝒕𝒕𝑨𝑨  for the chosen task (j) exceeded the 
required task threshold (𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑨𝑨
𝑻𝑻 ) and the patient followed the desired trajectory.   
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over a data window of 100 ms with 50% overlap, i.e., every 50 ms, 𝑘𝑘 =
1,2, … ,6 denotes the muscle and 𝑚𝑚 is the sample number.  The full control loop 
operated therefore at 20 Hz. The calculated momentary muscle activation level was 
compared to the threshold, as explained next.  
The threshold value (eq. 1) for the triggering muscle (𝑇𝑇ℎ𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 ) was set considering the 
muscle activation during the maximum voluntary contraction (𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 ) and the EMG 
channel baseline (𝐵𝐵𝐵𝐵𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 ). The threshold values for the triggering muscles 
corresponded to the 35% MVC plus 75% baseline level. The baseline corresponded 
to the maximum EMG activity at rest:   
𝑇𝑇ℎ𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 = 𝐵𝐵𝐵𝐵𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 + 0.35 ∙ (𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 − 𝐵𝐵𝐵𝐵𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 )     (eq. 1) 
This assured that the channel threshold was well above the EMG baseline and, at 
the same time, not too difficult to reach in order to avoid strong muscle fatigue. The 
calculated threshold could be also manually readjusted online by the therapist to fine 
tune the control for a specific subject.  
The training protocol comprised a set of single-DoF exercises, in which the task for 
the subject was to move the robot from the initial to the target position along the 
selected DoF (see section 3.1.2.2). The full control loop is depicted in Figure 3 (with 
switches in position (1)). 
At the beginning of each trial (𝑛𝑛 repetitions of a single-DoF task), the robot placed 
the subject’s arm in the initial position (𝑃𝑃�⃑𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼). If the activation of the triggering muscle 
was above threshold (𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 (𝑚𝑚) > 𝑇𝑇ℎ𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 ), the host PC incremented the desired 
position of the robot (𝑃𝑃�⃑𝑁𝑁𝑁𝑁𝑁𝑁𝐼𝐼𝑁𝑁𝐼𝐼𝑁𝑁𝑁𝑁 = 𝑃𝑃�⃑𝑁𝑁𝑁𝑁𝑁𝑁𝐼𝐼𝑁𝑁𝐼𝐼𝑁𝑁𝑁𝑁 + 𝑑𝑑𝐼𝐼𝐼𝐼𝑖𝑖) towards the end of the trajectory 
(𝑃𝑃�⃑𝐹𝐹𝐼𝐼𝐼𝐼𝐹𝐹𝐹𝐹). The robot started moving, providing assistive forces to the subject, and the 
distance to the desired position was monitored. If the distance was outside of the 
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predefined limits, i.e.,�𝑃𝑃�⃑𝑁𝑁𝑁𝑁𝑁𝑁𝐼𝐼𝑁𝑁𝐼𝐼𝑁𝑁𝑁𝑁 − 𝑃𝑃�⃑𝑚𝑚� < ∆�⃑ 𝑁𝑁𝐹𝐹𝐼𝐼ℎ, where 𝑃𝑃�⃑𝑚𝑚 is the measured position 
(sensor data) and ∆�⃑ 𝑁𝑁𝐹𝐹𝐼𝐼ℎ is the tolerance, the robot was lagging and further increment 
of the desired position was temporary disabled.  
The free movement was bounded through the use of virtual walls (∆�⃑ 𝑁𝑁𝐹𝐹𝐼𝐼ℎ) in order to 
not allow users to exceed certain limits. This tolerance was chosen by the 
physiotherapist. When the subject was unable to activate the muscle to exceed the 
threshold before the time-out period (subject too weak), the EMG-driven control loop 
was terminated, and then the robot fully took over the control to move the limb 
towards the end of the trajectory (𝑃𝑃�⃑𝐹𝐹𝐼𝐼𝐼𝐼𝐹𝐹𝐹𝐹). The therapist were also able to manually 
activate this option (“move to the end”) in order to avoid excessive patient’s fatigue.  
Importantly, this myoelectric control interface can be transferred to other active-
assistive robots for upper limb therapy. 
2.2.4 Torque Control 
The torque control was a threshold-based algorithm (switches in position (2) in 
Figure 3). To trigger the assistance of the robot, the subject had to exert enough 
force, so that the moment of force (task dependent) was above threshold. Visual 
feedback about the robot position (shoulder angle) and torque level was shown to 
the subject (see section 2.2.5). For online torque control, the momentary torque level 
𝑇𝑇𝑗𝑗(𝑚𝑚) for task 𝑗𝑗 = 1 … 4 was read from the torque sensors through the 
communication protocol (Figure 2(b)). The full control loop operated at 20 Hz. The 
momentary muscle activation level was compared to the threshold which was 
chosen by the physiotherapist. The torque threshold was also manually adjustable 
online by the therapist to fine tune the control for a specific subject.  
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The training protocol comprised a set of single-DoF exercises, in which the task for 
the subject was to move the robot from the initial to the target position along the 
selected DoF (see section 3.2.2).  
At the beginning of each trial (𝑛𝑛 repetitions of a single-DoF task), the robot placed 
the subject’s arm in the initial position (𝑃𝑃�⃑𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼). If the momentary torque level was 
above threshold (𝑇𝑇𝑗𝑗(𝑚𝑚) > 𝑇𝑇ℎ𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐸𝐸
𝑗𝑗 ), the host PC incremented the desired position 
of the robot (𝑃𝑃�⃑𝑁𝑁𝑁𝑁𝑁𝑁𝐼𝐼𝑁𝑁𝐼𝐼𝑁𝑁𝑁𝑁 = 𝑃𝑃�⃑𝑁𝑁𝑁𝑁𝑁𝑁𝐼𝐼𝑁𝑁𝐼𝐼𝑁𝑁𝑁𝑁 + 𝑑𝑑𝐼𝐼𝐼𝐼𝑖𝑖) towards the end of the trajectory (𝑃𝑃�⃑𝐹𝐹𝐼𝐼𝐼𝐼𝐹𝐹𝐹𝐹). 
The rest of the algorithm worked the same as for myoelectric control (see section 
2.2.3). The torque control loop was terminated and the robot fully took over the 
control to move the limb towards the end of the trajectory (𝑃𝑃�⃑𝐹𝐹𝐼𝐼𝐼𝐼𝐹𝐹𝐹𝐹) when the subject 
was unable to exert enough residual torque to exceed the threshold before the time-
out period (subject too weak). The therapist was able as well to manually activate 
this option as for myoelectric control. 
The minimum working value for the torque level that could be set for DoF 1, DoF 2 
and DoF 3 was 1 Nm, 0.5 Nm and 1 Nm, respectively, in order to avoid oscillatory 
motions of the robot. Oscillatory motions are a drawback of pneumatic robots and 
are due to a dynamic delay of the pressure response. The capability of the 
RehaARM robot to measure these torque values from 0.5 Nm to 1 Nm together with 
the compliant actuation of the RehaARM is not bad, it corresponds to the moment of 
force of small masses, 50 to 100 gr, respectively, rotating around an axis at a 
distance of 1 m. But it is limited, especially when the robot is supposed to assist 
more severely impaired patients. These users will always feel some residual 
apparent inertia and not free at motion.  
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2.2.5 Visual Feedback 
To assist and motivate the subjects when performing the task, they were provided 
with visual feedback (Figure 2(c)), depicting initial (𝑃𝑃�⃑𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼, green square), final (𝑃𝑃�⃑𝐹𝐹𝐼𝐼𝐼𝐼𝐹𝐹𝐹𝐹, 
red square) and current position (𝑃𝑃�⃑𝑚𝑚, blue ball). In the single-DOF target-tracking 
tasks (section 3.1.2.1), the desired position (target) was displayed (black ball) while 
the grey shaded area was not shown. If the robot was driven using myoelectric 
control (sections 3.1.2.2, 3.1.3.2 and 3.3), the black ball was not shown and the 
feedback (grey shaded area in Figure 2(c1)) included the momentary muscle 
activation level (𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 (𝑚𝑚), light blue square) together with the threshold level (𝑇𝑇ℎ𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 , 
black dashed line) were shown. If the robot was driven using torque control (section 
3.1.3.2), the black ball was not shown and the feedback (grey shaded area in Figure 
2(c1)) included the momentary torque level (𝑇𝑇𝑗𝑗(𝑚𝑚), light blue square) together with 
the threshold level (𝑇𝑇ℎ𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐸𝐸
𝑗𝑗 , black dashed line) were shown.  In addition, the area 
of wrong activation was indicated as a red box. The upper border of this area 
corresponded to zero activation of the triggered muscle.  If the muscle activation 
(light blue square) was within the area of the wrong activation, this indicated that the 
subject contracted wrong muscles (i.e., antagonists to the triggered muscle), pulling 
in the wrong direction. For torque control the upper border of this area corresponded 
to zero torque and if the momentary torque level (light blue square) was in this area, 
the subject was moving the arm in the opposite direction. 
The user’s central nervous system was incorporated into the control loop through a 
visual feedback in combination with kinesthetic, proprioceptive and tactile feedback. 
This allows the user to accomplish position control, with the RehaARM robot acting 




Clinical, kinematic and neurophysiological assessments were used in this project in 
order to determine the feasibility and efficacy of the RehaARM robot and its 
therapeutic concept.  
2.3.1 Clinical assessment 
The clinical assessments included impairment outcome measures and disability 
measures. 
2.3.1.1 Impairment outcome measures 
These outcomes assess impairments in body function, structure or system (including 
psychological). In this study, I just included body function impairments.  
- The Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA) is a 
disease-specific impairment index designed to assess motor function, 
balance, sensation qualities and joint function in hemiplegic post-stroke 
patients ([44], [45]). The score goes from 0 to 152. Minimum detectable 
change (MDC) and minimum clinically important difference (MCID) are not 
established6. 
- The upper extremity (UE) part of the Fugl-Meyer Assessment of Motor 
Recovery after Stroke (FMA-UE). This motor impairment test consists of 33 
items that assess voluntary movement, reflex activity, grasp, and coordination 
on a scale, with total scores ranging from 0 (no function) to 66 points (normal 
function). A MDC of 5.2 has been determined based on a study with a study 
with 14 subjects who suffered a single, unilateral stroke within 6 to 26 months 
before the admission into the study [46].The threshold for the MCID in 
patients with minimum to moderate chronic impairment after stroke is about 5 





points (range 4.25–7.25) depending on the movement domain of the test) 
[47].  
- Modified Ashworth Scale (MAS) assesses the amount of resistance or tone 
(spasticity) perceived by the examiner subjectively as the limb is moved 
through its full ROM. The tone can be no resistant or rigid [48], [49]. The scale 
goes for from 0 (no resistance) - 20 (rigidity). MDC and MCID are not 
established6. 
- Reaching Performance Scale (RPS) assesses the ability of the subjects and 
the quality of the movement in reaching an object (a cone). The cone is 
placed either close to the subject (4 cm) or farther away (30 cm). The subject 
is asked to reach the cone, pinching it on its point. The observer evaluates 
only the reaching movement and not the strength of the pinch. The score 
ranges from 0 to 36. Both tasks (close and far target) assesses the same six 
components using a 4-point ordinary scale; from 0 to 3. The six components 
are: trunk displacement, movement smoothness, shoulder movement, elbow 
movement, quality of grip and overall evaluation [50]. MDC and MCID are not 
established6. 
2.3.1.2 Activity scales 
These measures focused primarily on the identification of limitations in activity. 
- Functional Independence Measure (FIM) consists of 18 items assessing 6 
areas of function (self-care, sphincter control, mobility, locomotion, 
communication and social cognition). These fall into 2 basic domains; motor 
(13 items) and cognition (5 items) [51]. The score ranges from 18 (complete 
dependence/total assistance) to 126 (complete independence).The MCID has 
been identified for the stroke population based upon ratings of clinical change 
26 
 
made by physicians shortly following discharge from stroke rehabilitation [52]. 
The MCID is 22, 17 and 3 for the total FIM, motor FIM and cognitive FIM, 
respectively. We used here the motor FIM separately in order to assess the 
physical improvement. 
- Nine-hole Peg Test (NHPT) is a timed measure of fine finger dexterity [53], 
[54]. The subject is asked to insert nine pins into the pegboard as quickly as 
possible. The assessment in this study was done as the number of pins 
inserted by the subject in 50 s or by the time needed to insert the nine pins. 
We just used the number of inserted pins as NHPT variable. The time was not 
considered in this study. MDC and MCID are not established6. 
2.3.2 Kinematic assessments 
The active ROM of motion for the movements shoulder abduction (shoulder_ABD), 
shoulder flexion (shoulder_FLEX) and elbow flexion (elbow_FLEX) were assessed 
using the Pablo robot from Tyromotion. Pablo is a rehabilitation robot for arm and 
hand therapy. The Pablo system has a sensor handle equipped with position 
sensors to measure ROM of wrist, elbow and shoulder. The patient simply grasps 
the handle and the hand is fixed to the handle with a strap. The kinematic measures 
of the paretic limb took approx. 3 min. Subjects were instructed to perform the 
shoulder_ABD and the shoulder_FLEX with the elbow in 180° extension if possible 
depending on residual motor control. The therapist stopped the measurements if the 
patient compensated in order to avoid gains due to compensation. Patient started all 
movements with the hand in neutral position (0° pronation/supination). 
2.3.3 Neurophysiological assessments 
Voluntary movements are produced by the functional integration of several motor 
cortical areas, such as the primary and supplementary motor cortical areas, and 
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spinal circuitries. The synergistic activation of a set of muscles involved in a 
movement is a transformation of a low dimensional supraspinal signal set (known as 
motor primitives [42]) from the central nervous system (CNS) into a high dimensional 
signal set to the muscles. This transformation taking place in the spinal cord has 
been modeled in [55], [56], and is described in the so-called synergy theory. The 
synergy concept has two parts, the forward and the inverse model. The forward 
model (Figure 4(a)) describes the muscle patterns (time-invariant muscle synergies) 
generated by supraspinal motor commands (time-dependent coefficients or 
primitives) which can be obtained by measuring the surface EMG signals. The 
inverse model is the counterpart of the forward model and is used to obtain the 
supraspinal motor commands given the muscle synergies and the surface EMG 
signals. 
In this study, the forward model was used in order to obtain the muscle synergies of 
16 muscles for each task which subjects performed with the robot. The muscle 
synergies were obtained from the surface EMG signals. For this the acquired EMG 
signals were first high-pass filtered with a window-based finite impulse response filter 
(50th order, cutoff frequency of 50 Hz) to remove motion artifacts, rectified, low-pass-
filtered (50th order, cutoff frequency of 20 Hz) to remove noise, and then integrated 
over 25 ms intervals to obtain the muscle activation envelopes (𝐴𝐴𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝐼𝐼 ) which are 
always positive, Figure 4. The muscle synergies (𝐴𝐴) and the corresponding activation 
coefficients (𝑃𝑃) were extracted from the muscle activations envelopes 𝐴𝐴𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝐼𝐼 using 
the NMF algorithm [57]. The Non-Matrix Factorization (NMF) models the muscle 
activations as a linear combination (eq. 1) of several muscle synergies, each 
activated by a time-dependent coefficient. The muscle activations are always 
positive since a muscle can only contract actively, but not expand. Therefore, the 
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obtained primitives and synergies are also positive. For example, 𝐴𝐴𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸2  in (Figure 
4(b)) is a combination of the coefficients 𝑃𝑃1 and 𝑃𝑃2 weighted by muscle (𝑀𝑀2) from 
synergies 𝐴𝐴1  and 𝐴𝐴2. In this example, nMuscles equals 2, nSamples is the number of 
samples per task and nSynergies equals 2.  
𝑨𝑨𝑨𝑨 = 𝑷𝑷 𝑿𝑿 𝑨𝑨           (eq. 2) 
, 𝑨𝑨𝑨𝑨 is the matrix of muscle activation and has a dimension of [nMuscles X nSamples], 𝑷𝑷 is the matrix of activation coefficients 
(primitives) and has dimension of [nMuscles X nSynergies] and 𝑨𝑨 is the synergy matix and has a dimension of [nSynergies X 
nSamples]. 
 
Figure 4: Forward synergy concept for the control of the shoulder flexion/extension. In (a) from 
the motor cortex,  the low dimensional motor commands (primitives or activation coefficients, 
P) are sent to the spinal cord (S). In the spinal cord, P is transformed into the high dimensional 
muscle activation signals 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨  𝑨𝑨 = 𝟏𝟏,𝟐𝟐,𝟑𝟑, necessary to execute the intended movement. 
Finally, the muscle activation is recorded by the multi-channel bipolar surface EMG system. In 
(b), the model is schematically illustrated. It can be visualized how the recorded EMG signals 
can be reconstructed by linearly combining several time-invariant muscle synergies (𝑨𝑨𝟏𝟏,𝑨𝑨𝟐𝟐), 
each activated by a distinct time-dependent coefficient waveform (primitives, 𝑷𝑷𝟏𝟏, 𝑷𝑷𝟐𝟐). Each of 
the two synergies (𝑨𝑨, dimension 3 X 2) weights the coefficients (𝑷𝑷, dimension 2 X nSamples) in 
order to obtain three muscle activations (𝑨𝑨𝑨𝑨, dimension 3 X nSamples). ‘nSamples’ is the 
number of samples per task (nSamples = time*2048 Hz), the number of synergies is two, the 





In this way, the muscle synergies per task for each subject group (healthy subjects 
and patients) in each control modality, torque and myoelectric control, were 
calculated. The primitives were not used in this study, but they were inspected in 
order to confirm correct synergy extraction. As expected, the two primitives per task 
were two waveforms with alternating activity similar to the primitives (𝑃𝑃1,𝑃𝑃2) in Figure 
4(b). The number of muscle synergies for the NMF algorithm was set a priori to 2 
because we have single-DoF movements in two directions (e.g. Shoulder flexion and 
extension).  
NMF presents ambiguities of scaling and permutation like other factorization 
algorithms. The scaling ambiguity means that it is possible to identify only the 
relative, and not the absolute, activations between synergistic muscles. In this study, 
the scaling ambiguity was adjusted for by normalizing each synergy with respect to 
the level of activity of the most active muscle in that synergy. After this normalization, 
the maximum value in each column of the synergy matrix was equal to 1. The 
ambiguity of permutation is not relevant in the synergy context because there are 
just two synergies. 
The muscle synergies were then used to obtain the neurophysiological assessments 
EMG-S and TORQUE-S. The median of the muscle synergies of all healthy subjects 
(n=10) was used as the reference muscle activation for using the robot with 
myoelectric (EMG-S) or torque control (TORQUE-S). EMG-S is the overall similarity 
between sets of muscle synergies from the healthy subjects (reference muscle 
activation) and a patient when using myoelectric control. First, the similarity for each 
task with myoelectric control was calculated as the similarity (cosine similarity in eq. 
3) between the two synergies of the healthy subjects group (reference muscle 
activation for the corresponding task, 𝑨𝑨 in eq. 3) and the two synergies of a patient 
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for the corresponding task (𝑩𝑩 in eq. 3). The overall similarity for a patient was then 
the median of the similarities of all tasks. 
TORQUE-S is the overall similarity between sets of muscle synergies from the 
healthy subjects group (reference muscle activation) and a patient when using 
torque control. The overall similarity was calculated as for EMG-S. 𝑠𝑠𝑠𝑠𝑚𝑚𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 =
cos(𝜃𝜃) = 𝑨𝑨∙𝑩𝑩‖𝑨𝑨‖‖𝑩𝑩‖       (eq. 3) 
In other words, the similarity is a measurement that compares the relative 
contribution of the muscles involved in a movement. Therefore, EMG-S and 
TORQUE-S are measurements that compare the relative contribution of the muscles 
involved in a movement between healthy subjects (reference muscle activation) and 




3 Experimental Studies of the Newly Designed Robotic-
Assisted Therapy 
Three studies were performed to evaluate the result of this development. Section 3.1 
presents a first investigation on the feasibility of using a closed-loop myoelectric 
control system with nine healthy subjects and 12 stroke patients in a clinical set up. It 
also presents the acceptability and safety of the therapy. The results on both healthy 
subjects and stroke patients evidenced that the proposed RehaArm and the 
proposed therapeutic concept can be used in the clinical practice with a range of 
parameters to selectively and gradually modulate the motor response. 
Section 3.2 presents a second investigation on the practicability and ease of use of 
closed-loop myoelectric control versus closed-loop torque control of the RehaARM 
with 23 stroke patients. The results showed that myoelectric control with simple 
EMG-thresholding is more practical than torque control for robotic-assisted therapy 
of upper limb motor impairment. 
Finally, section 3.3 presents a third and final investigation on the effectiveness of 
using a robotic-assisted therapy of the upper limb with closed-loop myoelectric 
control on a population of 20 stroke patients with severe, moderate and mild 
impairments as assessed by the Fugl-Meyer Scale of the upper extremity.  
3.1 Study 1: A Novel Pneumatic EMG-driven Robotic System for 
Shoulder Rehabilitation after Stroke 
(This section is based on a manuscript submitted to BioMed Central for 
consideration [1]; therefore text, results and graphics taken from this manuscript are 




Objective. This engineering study presents the RehaArm robot, a novel 3DoF active, 
assistive robot designed for shoulder rehabilitation. The technical characteristics of 
the robot and the therapeutic modalities in closed loop control are described. 
Approach. The robotic-assisted therapeutic system was tested using two 
experimental protocols in order to demonstrate the robot operation in a clinical setup: 
(1) anti-gravity support during single and simultaneous DoF activation; and (2) anti-
gravity support and EMG-driven control. The experiments were performed with nine 
healthy subjects and 12 stroke patients. The 12 stroke patients only used 
EMG-driven control during four daily sessions. During myoelectric control, subjects 
had to actively and continuously drive the robot to complete the tasks in closed-loop 
using visual feedback of muscles signals. The robot assisted the patient if the EMG 
activity surpassed an individually settable EMG threshold value for each movement. 
The tasks were almost planar, single-DoF tasks for the shoulder. These tasks were 
functional, but yet simple, for training with more severely impaired patients. For 
myoelectric control, the subjects’ goal was to achieve a task completion rate (CR) of 
40 repetitions (5 repetitions x 4 single-DoF tasks x 2 directions) during 20 min.  Main 
Results. Using myoelectric control, the group of healthy subjects was able to execute 
40 task repetitions in 20 min. Over all days, the mild impairment group (group B, 
n = 6) performed significantly better (p<0.0001) than the severe-to-moderate 
impairment group (group A, n = 6). For group B, the median CR over all days was 39 
task repetitions per daily session within 20 min with Q3 = 40 and Q1 = 32.5 against a 
median CR of 24 repetitions with Q3 = 29 and Q1 = 14 for group A.  Both patient 
groups performed tendentially better over time. Consecutively from day 1 to day 4, 
group A executed a median of 18.5, 20, 27 and 24.5 task repetitions while group B 
executed a median of 34.5, 38.5, 38 and 40 task repetitions in 20 min, but there was 
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no significant difference in the CR over time. Significance. Patients including those 
more severely impaired were able to self-initiate and control the RehaArm robot 
using EMG-signals for shoulder therapeutic training, improving their movement 
completion rate over consecutive days. We conclude that the presented system can 
be flexibly, simply and safely employed in the clinic for shoulder therapy in 
impairments of upper limb motor function for a larger stroke population with different 
impairments: severe, mild and moderate.  The system can be used with a range of 
parameters to selectively and gradually modulate the motor response. 
3.1.2  Methods 
The system has been tested in two main conditions: the evaluation of the Robot 
Compliant Operation (section 3.1.2.1) and the Clinical Evaluation Using EMG-
Control (section 3.1.2.2). Two trained physiotherapists were involved. One 
physiotherapist contributed to the experimental design and the other was in charge 
of executing the experimental protocols. In addition, an engineer (mostly the author 
of this thesis) was always present during the sessions.  
3.1.2.1 Robot Compliant Operation 
The test included three healthy male subjects (age = 29 ± 6 yrs).  
The robot provided antigravity support. It generated forces to hold the limb in a 
desired position. Meanwhile, the subject was required to exploit the robot compliance 
 
Figure 5: Visual feedback to the subject displayed on the monitor placed in front of the subject 
for the single-DoF target tracking task (HORZ ADD/ABD) (a) and for the EIGHT target-tracking 
task, a simultaneous combination of two single DoF tasks: HORZ ADD/ABD and FE (b). 
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and actively move the limb around the current set point, as defined by the 
experimental task. For these tests, the myoelectric control (section 2.2.3) was not 
employed, and the robot command was only to stay in the reference position. When 
the subject deviated from the reference position, his movement was counteracted by 
the corrective torques generated by the robot. Maximal possible deviation from the 
reference depended on the subject’s effort and the robot maximal torque, where the 
latter is an adjustable parameter. Essentially, this protocol was a combination of 
assistive (antigravity support) and resistive (restorative torques) training, where the 
torque of each training modality could be adjusted from zero to the maximal torque 
that the robot can generate.  
The starting position of the shoulder was horizontal adduction (45°), plus flexion 
(70°) and 0° of humeral rotation. In the following, the two tasks comprised in the 
protocol are explained.  
For the single-DoF target–tracking tasks (Figure 5), the subjects had to follow a 
target (black ball) as it moved along a straight line from the initial to the final position 
at a constant speed. Two movement trajectories were used, a straight line along 
HORZ ADD/ABD (Figure 5(a)) or along FE DoF. In the EIGHT target-tracking task 
(Figure 5(b)), the subjects tracked a trajectory shaped as a number eight positioned 
parallel to the coronal plane, activating two DoFs simultaneously (i.e., HORZ 
ADD/ABD and FE). The direction of movement along the trajectory was displayed to 
the subject. 









C1 10 0 10 0.01 
C2 10 0 30 0.01 
C3 10 10 10 0.01 
C4 10 10 30 0.01 
C5 10 10 30 5 




In the single-DoF target-tracking tasks, we tested six conditions characterized by 
different values of the robot configuration parameters (Table 2 and Table 1). Each 
subject performed 10 repetitions in each condition. In the EIGHT task, the maximum 
resistive torque was changed from soft (i.e. minimum torque) to stiff (i.e. maximum 
torque) in each DoF individually as well as in both DoF concurrently, resulting in four 
conditions in total (Table 3), while the parameter “holding time” was not applicable 
for this task. Each subject performed three repetitions in each condition. This 
protocol was executed in only one daily session of one hour including subject 
preparation. 
3.1.2.2 Clinical Evaluation Using EMG-Control 
Six healthy volunteers (two male and four female subjects, 58.5 ± 14 yrs, right 
dominant) and 12 right hemiparetic stroke patients (Table 4) meeting study inclusion 
criteria participated in the study. The inclusion criteria for stroke patients were: first-
ever supratentorial stroke (ischemic and/or hemorrhagic) in the left hemisphere, with 
the score between 1 and 3 in the upper limb sub-item of the Italian version of the 
National Institutes of Health Stroke Scale (IT-NIHSS). The IT-NIHSS score was 
considered as a reliable criterion for assessing the existence of residual voluntary 
motor contraction, which was a necessary condition to use the myoelectric control. 
The study exclusion criteria were: Mini Mental State Examination (MMSE) 
Table 2: robot configuration setting 
Variable Effect Description Values used 
 [min, max] 
Maximum 
torque 
Set only for the DoF involved in the task; it limits the 
corrective force that the robot exerts on the subject’s arm 




Larger deviation from the reference position results in the 





Forces due to the viscosity (i.e. higher motion speed 




Time to hold the robot at the final position for the buildup 
of the resistive robot torque 
[0.01, 5] [s] 
*The maximum torque around the DoF was 5 Nm in the EIGHT task and 10 Nm in the ONE-DoF task, respectively. 
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score < 20/30, score (tau points) in the Token Test for verbal comprehension < 58/78 
and non-stabilized fractures. 
The patients were classified in two groups according to the FMA-UE. Patients with 
an FMA-UE score <= 38/66 were included in the severe-to-moderate group (A) and 
those with a FMA-UE score > 38/66 were included in the mild stroke group (B) 
(Table IV). Patients were classified according to their motor impairment in order to 
homogenize the subject groups and achieve more relevant clinical insights, as the 
previous studies have demonstrated that the treatment outcome can depend 
substantially on the level of impairment at baseline [26], [58].  
The exercises included movements along a single DoF (Table 5), similarly to the 
target-tracking tasks described in the previous section 3.1.2.1. However, in this 
protocol subjects used myoelectric control to move the robot (myoelectric control 
with simple EMG-thresholding, section 2.2.3), were not required to track a target and 
were able to move at their own pace. The HORZ ADD/ABD, ADD/ABD, FE and IE 
single-DoF movements, selected as the clinical tasks, represent basic shoulder and 
scapula movements. The single-DoF movements 1, 2 and 4 (Table 5) are performed 
mainly by activating the shoulder muscles pectoralis major and the three deltoids, 
with the partial involvement of the rotator cuff muscles. For example, during 90° 
Table 3: conditions for the eight tracking task 
Condition FE DoF  
Maximum torque [Nm] 
ABD DoF 





E1 0 0 5 50 
E2 0 5 5 50 
E3 5 0 5 50 
E4 5 5 5 50 
 
Table 4: patients characteristics for study 1 (n = 12)  
 Frequency median Q1-Q3 
Age  68.5 55.1-76.4 
Gender (M / F) 8 / 4   
Months since stroke  4.8 3.8-7.2 
FMA-UE (≤38 / >38) 6 / 6   
*Q1 and Q3 are the first and third Quartile. 
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flexion, 60° are supported by the glenohumeral joint (humeral elevation) and 30° by 
the scapular muscles (upward rotation of the scapulothoracic joint), which is known 
as the 2:1 ratio scapulohumeral rhythm [40]. The IE exercise (Table 5) activates 
more the muscles controlling the scapula, such as, rotator cuff muscles, teres major 
and infraspinatus (Figure 1 (d)). 
For each exercise, a trained physiotherapist selected the triggering muscles based 
on the pilot tests. The triggering muscle was always either the most activated one or 
it belonged to the group of most activated synergistic muscles (Table 5). The 
individual maximum ROM of the shoulder for each single-DoF task was adjusted by 
the physiotherapist using the graphical user interface (GUI) during the first session 
(and if necessary, readjusted in the following sessions). The physiotherapist moved 
the exoskeleton along the task DoF from minimum to maximum excursion, so that 
the obtained ROM corresponded to the comfortable ROM for the specific patient. 
To obtain the EMG baseline of each channel (𝐵𝐵𝐵𝐵𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 ), the robot was positioned in 
55° of horizontal adduction, 35° of flexion and 0° of rotation. The subject was asked 
to relax and the EMG signals were recorded for 1s. The EMG baseline was 
computed as the maximum value of the rectified envelope of the recorded EMG 
signal. To measure the MVC of the triggering muscles (𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 ), the robot was 
positioned in the middle between the initial and final positions in the task for which 
that muscle was the trigger muscle (Table 5). Subsequently, the subject was asked 
to push the exoskeleton as strong as possible towards the final position (task 
















2 ADD Teres major ABD Medium 
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relevant direction) maintaining the contraction for 3 s. The 𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘  was computed as 
the maximum value of the rectified envelope of the EMG signal recorded in the last 
second. The EMG baseline and MVC value were calculated at each trial and 
session. One trial consisted of 5 repetitions of a single-DoF task; therefore the 
session compromised four trials, one trial per task. 
The parameters for the myoelectric control were set to 𝑑𝑑𝐼𝐼𝐼𝐼𝑖𝑖 = 5°, 𝑠𝑠𝑜𝑜𝑜𝑜𝐼𝐼= 40s and ∆�⃗ 𝑁𝑁𝐹𝐹𝐼𝐼ℎ  
to 13°, 7°, 10° and 7° for DoF1 to DoF4, respectively. The maximum torque was 
configured to 20 Nm for HORZ ADD/ABD and IE, and 30Nm for ADD/ABD and FE 
DoFs. The torque was set to high values, so that the robot supported the arm along 
the selected task, providing active assistance to the patient while performing the 
movement, and at the same time limiting the excursions along the other DoF. 
Patients performed the protocol in four consecutive days, one session daily. The 
session lasted for approximately 40 min including a 10-min preparation time. During 
each session, the four single-DoF tasks were executed first passively by the robot 
(10 min) to familiarize the patients to the robot and to warm up the muscles. 
Subsequently, the subjects actively performed the tasks by using EMG-driven control 
(20 min). The goal was to achieve a CR of 40 repetitions (5 repetitions x 4 single-
DoF tasks x 2 directions) during 20 min. At the beginning of each trial, the subject 
was positioned at the starting position for the respective task (Table 5). Forty 
repetitions was the number of repetitions that the healthy subjects were able to 
perform in 20 min without strong fatigue, and this was therefore adopted as the 
desired goal for the patients due to limited therapy duration. In the case that a patient 
reached 40 repetitions under 20 min, the session was stopped. The sequence of 
tasks was randomized daily. 
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The subject was instructed to make an effort to move the robot towards the final 
position (𝑃𝑃�⃑𝐹𝐹𝐼𝐼𝐼𝐼𝐹𝐹𝐹𝐹). Doing this, he/she activated the triggering muscle. The subject was 
then expected to monitor the visual feedback (Figure 2(c1)) and modulate the effort 
so that the light blue square (𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 (𝑚𝑚)) moved out of the red zone in the direction of 
the green arrow, surpassing the dashed black line (𝑇𝑇ℎ𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 ). As long as the subject 
maintained the light blue square above the threshold line, the robot assisted the 
movement towards the final position. Once activated, the robot moved at the 
maximum speed (5 /̊s). The total duration of a repetition, and therefore the number of 
completed exercises (task completion rate) within the session time for EMG control 
(20 min) depended on how well the subject was able to maintain the muscle 
activation above the threshold. 
The EMG signals were displayed continuously on the computer screen to the 
physiotherapist during the session, so that hypotonic and compensatory muscle 
activity were immediately detected and corrected by the physiotherapist. The EMG 
signals were therefore used as an additional tool for the physiotherapists in order to 
enhance selective control of proximal shoulder muscles. 
3.1.3 Data Analysis 
The recorded EMG signals were manually inspected in order to remove those task 
repetitions with evident artifacts due to the electrode displacements or accidental 
contacts with the robotic parts. 
3.1.3.1 Evaluation of the Robot Compliant Operation 
For the single-DoF target-tracking tasks, the average level of muscle activation 
during the task was estimated as the mean value of the Root Mean Square (RMS) 
computed over the data windows of 128 ms with 50 ms of overlap. The mean RMS 
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was normalized to the maximum mean RMS for the specific muscle across tasks and 
conditions which was obtained consistently in C5. 
For the EIGHT task, the linear EMG envelope was plotted in order to assess the 
modulation of the EMG activation during the entire execution of the task. The 
envelopes were normalized to the maximum of the envelope for the specific muscle 
across tasks and conditions. 
3.1.3.2 Clinical Evaluation with EMG-driven Control 
The activation profiles for the triggering muscles per task,  𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 , were normalized by 
the MVC of the triggering muscle obtained during the task calibration (𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝐸𝐸𝐸𝐸𝐾𝐾 ) in 
order to compare the EMG activity of triggering muscles taskwise among subjects.  
The activation profiles for the scapular muscles per task,𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸
𝐼𝐼𝑁𝑁𝑡𝑡𝑁𝑁𝑡𝑡,𝐼𝐼𝐼𝐼𝑖𝑖𝑡𝑡𝐹𝐹𝑡𝑡𝑁𝑁𝐼𝐼𝐼𝐼𝐹𝐹𝐼𝐼𝑜𝑜𝑡𝑡, were 
normalized using MVCs (𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝐸𝐸𝐸𝐸𝐼𝐼𝑁𝑁𝑡𝑡𝑁𝑁𝑡𝑡 and 𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝐸𝐸𝐸𝐸
𝐼𝐼𝐼𝐼𝑖𝑖𝑡𝑡𝐹𝐹𝑡𝑡𝑁𝑁𝐼𝐼𝐼𝐼𝐹𝐹𝐼𝐼𝑜𝑜𝑡𝑡) obtained during the IE task. 
The infraspinatus activity was computed for the movements HORZ ABD, ABD and 
FLEX, while the activity of the teres was determined for HORZ ADD, ADD and EXT, 
because these muscles are mainly active during the respective tasks. 
The maximum values of the activation profiles for the triggering and scapular 
muscles (𝑚𝑚𝑠𝑠𝑚𝑚�𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 �) for each task and subject group were calculated as the 
median of the maximum activation values for each trial.  
To assess the performance in completing the exercise, the CR was noted for each 
subject in each task, by counting the number of exercises in which the subjects 
reached the final position using active myocontrol. This does not include the 
repetitions in which the time out period expired, and the robot therefore completed 
the movement on behalf of the passive subject.  
The median completion rate over all days and the patients’ subjective evaluation on 
the ease of use of EMG control for group A were compared with group B using the 
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Mann-Whitney U Test. For each group, the comparison of CR among days was done 
using the Friedman test. The comparison of the maximum values of the activation 
profiles 𝑚𝑚𝑠𝑠𝑚𝑚�𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 � among groups was done using Kruskal-Wallis ANOVA by Ranks 
and Median Test, followed by post-hoc multiple comparison of mean ranks using 
Dunn test. Nonparametric tests were used because the data distributions were not 
normal, as determined by the Shapiro-Wilk Test. The statistical differences and 
normality rejections was tested at a significance level of p<0.05. In the texts, plots 
and tables the level of statistical significance is indicated as follows: ‘∗’ for p<0.05, 
‘∗∗’ for p<0.01, ‘∗∗∗’ for p<0.001 and ‘∗∗∗∗’ for p<0.0001. The data is represented in 
boxplots with the median, First (Q1), Third Quartile (Q3), min/max values and 
outliers. The min/max values are the values whose distance from Q1 downwards or 
Q3 upwards does not exceed 1.5 times the box height. The box height is the IQ-
range (Q3-Q1). The outliers are the values whose distance from Q1 downwards or 
Q3 upwards exceeds 1.5 times the box height.  The statistical tests were performed 
in STATISTICA v12 (StatSoft, USA). 
3.1.4 Results 
3.1.4.1 Evaluation of the Robot Compliant Operation 
The mean activity of the primary agonist muscles across different conditions for the 
selected single-DoF target-tracking tasks is displayed in Figure 6. The activity of the 
target muscles was modulated as the task and robot configuration parameters were 
changed, and this modulation was well controlled for all tested subjects, i.e., the 
primary agonist muscle was recruited through a range of activity levels by changing 
the conditions from C1 to C6.  
Increasing the maximum torque during both slow (C1 vs C3 in Figure 6(a-c)) and fast 
movements (C2 vs C4 in Figure 6(a, b) as well as increasing the movement speed in 
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both soft (C1 vs C2 in Figure 6 (a, b)) and stiff modes (C3 vs C4 in Figure 6(a, b)) 
resulted in the higher values of the mean muscle activity over the repetitions. The 
muscle activity increased when the subject was instructed to stay at the target for a 
longer time during fast movements and stiff mode (C4 vs C5 in Figure 6(a, b)) and 
slow movements and soft mode (C1 vs C6 in Figure 6(c)) due to a prolonged buildup 
of the robot resistive torques. Overall, the highest mean RMS value was registered 
when the holding time, movement speed and the robot maximum force were set to 
the high values (condition C5 in Figure 6(a-c)). Therefore, in all the conditions, the 
selective activation of muscles was achieved by manipulating the robot configuration 
parameters. The primary agonists were the most active as the robot provided gravity 
compensation during the movement. 
A similar modulation of EMG activity was observed during the EIGHT task. Figure 7 
shows the activation of the pectoralis major and teres major in one representative 
subject while traversing the trajectory, when the robot was in the soft mode (Figure 
7(a, c)) and when the stiffness was increased (i.e., stiff mode), but only along the 
HORZ ADD/ABD DoF (Figure 7(b, d)). Pectoralis major (Figure 7(a)) was most 
active while moving along the diagonal parts of the trajectory, i.e., from the center 
 
Figure 6: Modulation of EMG activity of triggering muscles during the target-tracking single-
DoF by changing task and configuration parameters. Normalized mean value of the RMS of the 
EMG-signals recorded from (a) Posterior Deltoid of subject 1 during horizontal abduction 
(HORZ ABD), (b) Pectoralis Major of subject 2 during horizontal adduction (HORZ ADD) and (c) 
Middle Deltoid of subject 3 during shoulder abduction (ABD) across the condition Ci, i = 1, …, 6 
of Table II. The terms (soft, stiff) and (slow, fast) are descriptive names for the (minimum, 
maximum) values in the columns “Maximum torque around the DoF” and “Speed of 
Movement” in Table II, respectively. 
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upwards, which corresponds to a combination of flexion and horizontal adduction, 
and from the center downwards, corresponding to a combination of extension and 
horizontal adduction. During the horizontal segments of the trajectory (top and 
bottom arches), which represent horizontal abduction, the muscle was almost silent. 
This pattern of activity agrees with its biomechanical function [59], i.e. it is a flexor 
and horizontal adductor of the shoulder. 
When the stiffness was increased selectively along HORZ ADD/ABD, the muscle 
reproduced the same overall pattern, but with a higher level of activation. 
Importantly, the increase in activation was observed only in those muscles involved 
in the HORZ ADD/ABD such as Pectoralis Major (Figure 7(b)), Anterior and Posterior 
Deltoids. Indeed, as shown in Figure 7(c, d), no major EMG modulation was 
observed in the teres major between the two conditions since its principal actions are 
shoulder adduction and shoulder internal rotation [59]. Therefore, by manipulating 
the robot configuration parameters, the selective recruitment of muscles was 
achieved even during the exercise that included simultaneous activation of two DoF. 
 
Figure 7: Modulation of EMG activity of pectoralis major and teres major during an EIGHT task 
when modifying the parameter maximum torque along HORZ ADD/ABD in one representative 
subject. Linear envelopes of pectoralis major (a, b) and teres major (c, d) in both soft (a, c) and 
stiff (b, d) mode, respectively. The annotation [FE, HORZ ABD/ADD] indicates the maximum 
torque setting around the FE and HORZ ADD/ABD DoF, respectively. 
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3.1.4.2 Clinical Evaluation with EMG-driven Control 
The recorded signals for the movement along IE DoF for a representative patient 
with a mild impairment are illustrated in Figure 8 to demonstrate the operation of the 
robot. As long as the momentary EMG activation level of the teres major muscle was 
over the threshold ( 𝑇𝑇ℎ𝐸𝐸𝐸𝐸𝐸𝐸,𝐼𝐼𝑁𝑁𝑡𝑡𝑁𝑁𝑡𝑡= 9 mV, see green signals in Figure 8(a)), the robot 
actively assisted the patient until completing the task of internal rotation (I), i.e., 
DoF3 changed from -8.4° to 37.6° (Figure 8(b, c)). Similarly, while the infraspinatus 
muscle was over the threshold (𝑇𝑇ℎ𝐸𝐸𝐸𝐸𝐸𝐸,𝐼𝐼𝐼𝐼𝑖𝑖𝑡𝑡𝐹𝐹𝑡𝑡𝑁𝑁𝐼𝐼𝐼𝐼𝐹𝐹𝐼𝐼𝑜𝑜𝑡𝑡=17.6 mV, see light blue signals in 
Figure 8(a)), the robot provided assistance during external rotation (E), i.e., the DoF3 
 
Figure 8: Activation profile of six shoulder muscles, 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝟏𝟏 ,… 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝟔𝟔  (a) and robot position (b) 
when a representative patient with a mild impairment was performing the exercise of 
internal/external rotation, DoF3 (c) using myoelectric control. The 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨  were the activation 
profiles determined and saved online during the session. The external rotation corresponded 
to a displacement of 46 degrees (from 37.6° to -8.4°) and the internal rotation corresponded to 
the reverse movement. The patient moved mostly along DoF3 (task direction), but the 
movement was not entirely planar, since there were some excursions along DoF1 and DoF2 
(approx. 10° and 2.9°, respectively). The teres major and infraspinatus muscles were the 
triggering muscles for the internal and the external rotation, respectively. The activity of these 
muscles was strong enough to drive the robot progressively through the task without the 
robot’s passive assistance. In (b) R(t) is the reference position which the patient should follow 
and O(t) is the patient’s generated trajectory. 
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changed from 37.6° back to -8.4° (Figure 8(b, c)). This patient tended to move the 
robot also around DoF1 while rotating the shoulder, but the robot limited the 
excursions along this DoF since it was configured to be stiff around DoF1 (maximum 
restorative torques set to 20 Nm). The patient had no problem in activating the 
triggering muscles consistently above the threshold and completing the tasks without 
the robot assistance (Figure 8(a)). 
Summary results of the CR for the two patient groups over consecutive days are 
plotted in Figure 9. All healthy subjects consistently reached the maximum number of 
repetitions (40) in each session, and the results for them are therefore not shown. 
The mild impairment group B performed significantly better (p<0.0001) than the 
severe-to-moderate impairment group A over all days. The overall median CR was 
39 task repetitions, Q3 = 40, Q1 = 32.5 for group B and the overall median CR was 
24 task repetitions, Q3 = 29, Q1 = 14 for group A. Group A increased the 
 
Figure 9: Completion rate (CR) for group A and group B using the EMG-driven control system 
over consecutive days (black boxplots) and median completion rate (CR) for group A and 
group B over all days (dashed grey boxplots). The target CR per session for each control 
modality was 40 repetitions (5 repetitions x 4 single-DoF tasks x 2 directions). There was a 
tendency towards a higher number of repetitions over consecutive days for both groups, but 
no significant difference was found. Group B executed a significantly higher number of 
repetitions over all days (p<0.0001, grey asterisks and bar) in comparison to group A. 
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performance over time. The median CR was 18, 20, 27, and 24 from day 1 to day 4, 
respectively. Group B exhibited a similar trend, increasing the median CR from 34 on 
day 1 to 38, 38, and 40 on the remaining days. However, the differences over 
consecutive days were not statistically significant for any of the groups. 
Figure 10 compares the muscle activation profiles �𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 � between the two patients 
with mild and strong impairment, and a heathy subject. The stroke patients exhibited 
a reduced and uncoordinated muscle activity with respect to the healthy subject. 
During HORZ ADD/ABD, the healthy subject (Figure 10(a)) generated well-defined 
bursts of activity in the triggering muscles, i.e., pectoralis and posterior deltoid. The 
bursts were above the threshold and out of phase, to drive the robot along the task 
DoF in both directions. The activity of the other two deltoid muscles and infraspinatus 
were in phase with the posterior deltoid, while the teres major supported the 
shoulder with a consistent activation during the entire movement in both directions.  
During the same movement, the representative mild patient (Figure 10(b)) exhibited 
visible bursts of activity of the pectoralis muscle, although the activation was barely 
crossing the threshold level. The bursts in the other triggering muscle (posterior 
deltoid) were not that clearly defined which also holds for the other two deltoids and 
infraspinatus. The mild patient accomplished 36 repetitions in the session and did 
not trigger the time out. The representative severe-to-moderate patient generated 
visible bursts of activity in the pectoralis muscle, but the other triggering and 
supporting muscles were almost silent, with some spontaneous activation during the 
tasks (Figure 10(c)). The severe patient accomplished only 8 repetitions in the 
session and triggered the time out 32 times, activating the robot to take over and 
passively move the arm to the end of the trajectory. 
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The maximum activity of the rotator cuff muscles (Table 6) for group A was 
 
Figure 10: Activation profiles of six muscles during the execution of a HORZ ADD/ABD for a 
representative healthy subject (a), a mild patient (b) and a severe-to-moderate patient (c). The 
threshold values for the triggering muscles corresponded to the 35% MVC and the baseline 
corresponded to the maximum EMG activity at rest. Note the similar threshold values for the 
representative healthy subject and mild patient. While these values for the representative 
severe patient were markedly lower, especially for the posterior deltoid. The EMG activity of 
the pectoralis was similarly strong for all subjects (See also table VI). Note that the axes range 
for each plot is different, e.g. for the infraspinatus, teres and deltoid muscles of the severe 




significantly reduced (p<0.05) in comparison to the healthy subjects during all tasks 
except in HORZ ABD for the infraspinatus. The median values for the rotator cuff 
activation levels were higher in group B compared to A, but not significant 
differences were found except for the teres activation in the internal rotation. 
Contrarily, there were no significant differences in the rotator cuff activations 
between group B and the healthy subjects, except for the infraspinatus in the flexion. 
The maximum activation values of the triggering muscles (Table 7) significantly 
differed between the healthy subjects and the group A (p<0.05) for all tasks except  
for the pectoralis activity in HORZ ADD. Contrarily, there were no significant 
differences between group B and the healthy subjects. Finally, the median values for 
the rotator cuff activation levels were higher in group B compared to A, but not 
significant differences were found except for the teres muscle in ADD and internal 
rotation and posterior deltoids in the extension. 
Table 6: maximum values of emg activity of the rotator cuff muscles for each task (median; mean ± std) 

















Group A 4.3; 
4.2 ± 1.4+ 
5.7; 
6.7 ± 3.5 
3.9; 
4.8 ± 2.5+ 
5.4; 
5.7 ± 2.7+ 
3.9; 
4.3 ± 1.7* 
6.9; 
7.7 ± 4.2+ 
4.4; 
6.3 ± 4.6+ 
4.8; 
4.8 ± 1.7+ 
Group B 7.5; 
9.3 ± 6.3 
7; 
6.2 ± 3.2 
10.5; 
12.4 ± 6 
6.2; 
7.3 ± 3.8 
16.9; 
15.4 ± 3.6 
15.7; 
13.2 ± 4.9 
11.4; 
13.4 ± 4.6 
3.4; 




17 ± 8.7 
15.6; 
14.9 ± 8.9 
16.1; 
19 ± 9.4 
13.3; 
12.7 ± 3.8 
20.4; 
25.5 ± 17.1 
21.8; 
23.1 ± 6 
18.8; 
20.9 ± 7.2 
23.8; 
22.8 ± 13.9 
The values are in %. An asterisk (*) or a degree symbol (+) for group A means that the values of this group significantly differed (p<0.05) 
from the values of group B and the healthy subjects or just from the values of the healthy subjects, respectively. A degree symbol (°) for 
group B means that this group significantly differed (p<0.05) from the values of the healthy subjects. 
Table 7: maximum values of emg activity of the triggering muscles for each task (median; mean ± std) 
Task Exercise 1 Exercise 2 Exercise 3 Exercise 4 
 HORZ 
ADD 














Group A 9; 
11.2 ± 7.7 
8.1; 
7.7 ± 4.3+ 
3.6; 
3.9  ± 1.2* 
5.8; 
5.8 ± 3.3+ 
(/) (/) 6.7; 
6.6 ± 2.4* 
7.4; 
7.2 ± 4.4+ 
Group B 18.3; 
17.1 ± 7.2 
13.1; 
12.7 ± 3 
10.5; 
13.4 ± 6.2 
11.3; 
11.1 ± 2.2 
(/) (/) 13.3; 
14.4 ± 3.8 
12.3; 




18.9 ± 6.5 
15.1; 
18.8 ± 11.6 
14.8; 
16.9 ± 10.3 
13.9; 
13.5 ± 4.2 
(/) (/) 12.7; 
16 ± 8.8 
15.1; 
14.9 ± 4.3 
The values are in %.  (/) The values for the Infraspinatus and Teres for exercise 3 here are the same as in the previous table because these 
muscles were the triggering muscles for this task. An asterisk (*) or a plus symbol (+) for group A means that the values of this group 





Rehabilitation robots can be effective for motor training since they can reproduce 
exercise protocols in a consistent manner, provide multi-modal feedback to the user 
(e.g. tactile, visual) and customize the interventions based on individual physical 
impairments for task-specific training [23]. A suitable robot for upper limb stroke 
rehabilitation should be comfortable, safe and easy to attach to the patient’s arms. 
Moreover, the robot should also allow the interaction between the therapist and the 
patient during an exercise in order to allow the therapist to be an active supervisor of 
the training.  
In this engineering study, the novel RehaArm robot for the rehabilitation of the 
shoulder in stroke patients has been introduced. Due to a pneumatic actuation, 
RehaArm is an inherently compliant robot. Therefore, it provides a soft contact with 
the patient, responding promptly to his/her movements and/or interventions from the 
therapist. The patient was comfortably seated on the robot chair and his/her arm was 
simply strapped to the robotic arm. Compliant operation and the slow movement 
make the robot a safe platform, which can be used to provide the therapy even in an 
early stage after stroke. The motor training with RehaARM allows for task-specific 
training of the shoulder, the first joint to be mobilized in the acute phase. The tasks 
were functional and permit the shoulder training for ADLs. For example, the shoulder 
flexion is a function required in lifting the arm for grasping an object.  
The RehaARM system with myoelectric control permitted patients – even those 
severely affected – to understand how to initiate, continue and complete a motor task 
activating the primary muscle, and thus synergistic muscles for the execution of a 
certain task. The elbow and the hand joint were fixed and this facilitated the shoulder 
tasks. Even severely impaired patients were able to drive the robot into a movement 
while mild patients were able to actively perform brighter shoulder movements. 
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Therefore, the RehaARM system can be used for-task specific training according to 
individual needs. 
We demonstrated that RehaArm can be used to implement different exercise 
modalities such as compliance-based training, EMG-driven control or a combination 
of both. We performed a preliminary test in which different robot configuration 
settings (speed, stiffness), experimental task parameters (trajectory length, holding 
time), and experimental paradigms (single- and multi-DoF activation) have been 
tested in healthy subjects to investigate the properties and usability of the robotic 
device.  
The results demonstrated that the motor response of the volunteers was selectively 
modulated and in a well-controlled manner by changing the experimental task and 
robot configuration parameters. The activity in the specific muscle (or muscle group) 
was adjusted gradually to a range of levels (Figure 6). Importantly, there is flexibility 
in implementing these adjustments; several parameters are available to modulate 
the muscle activation (see Table 2), and these can also be combined for the 
cumulative effect (and these can be also combined for the cumulative effect (as done 
in the single-DoF target-tracking task experiment). Therefore, the exercise can be 
adjusted according to the needs of an individual subject. For example, at the 
beginning of the training, the patient could start with a soft robot, small excursions 
and a touch and go single-DOF tracking task. Later on, as his/her status improves, 
the stiffness and/or trajectory length and/or time on target could be increased, posing 
a more challenging task to the subject. There is a strong evidence that adapting the 
task difficulty to the current status of the patient promotes the recovery [60]. In the 
multi-DoF movement (EIGHT task), the muscle groups that were active during 
movements along a certain DoF were additionally loaded by increasing the robot 
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resistance selectively along that specific DoF (Figure 7). The parameters used to 
regulate the muscle activity during single-DoF movements can be applied in the 
same way in a multi-DoF exercise.  
Finally, we have demonstrated that the active robot assistance triggered by the user 
using muscles signals (i.e. EMG-driven control) can be used for an experimental 
protocol in a clinical setup. Indeed, mild and severe-to-moderate impaired stroke 
patients were able to drive the robot by producing EMG activation in the primary 
agonist (triggering) muscle along the selected task, which resulted in smooth 
movement trajectories (Figure 8 and Figure 10). The mild and severe-to-moderate 
patients were able to use the EMG-driven control and performed better over the four 
consecutive days. The mild patients performed at day 4 similarly well (median CR ~ 
40) to the healthy subjects group who all executed 40 task repetitions in 20 min on 
the first day. The severe-to-moderate impairment group executed 27 and 24.5 
(median) task repetitions on day 3 and day 4, respectively. That is approximately 
67% and 61% of the performance of the healthy subjects and mild patients. Both 
patient groups consistently improved over time. We used completion rate (CR) as a 
measure of performance. This measure reflects better voluntary control of the target 
muscles and a better understanding of using the system. This is not the result of only 
compensatory mechanisms because physiotherapists could adjust the level of 
difficulty of the training to the patient's ability to correct for compensation. The 
increment of CR which we obtained does not necessarily indicate clinical 
improvement. The length of the experiment was four days and this is too short time 
to achieve clinical improvements. 
RehaArm with the EMG-driven control interface can therefore allow severe and 
moderately impaired patients to train arm motions, which are demanding and 
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substantially above of what they could accomplish on their own (i.e., without gravity 
compensation and active assistance). Verbally, patients reported the motivating 
factor of using RehaArm in comparison to conventional therapy because they felt 
that they performed exercises more independently without the physiotherapist’s 
physical assistance. This is a very motivating factor, especially for severe patients 
who can just be treated passively in conventional therapy [61]. Daily, the 
performance (CR) was shown to the patients and they were excited if they realized 
that they were able to do more. It is well known that concentration and engagement 
of the patient during the therapeutic treatment are important factors for recovery [62].  
The single-DoF tasks were not perfectly planar and deviated depending on subjects’ 
motor condition and anatomy. For example, the flexion task was not perfectly a 
flexion. It was rather a flexion with horizontal adduction and external rotation. This 
implies that while mainly activating DoF2, the other two DoFs were also slightly 
activated. This was the case also for the other tasks (e.g. Figure 8 for IE). Training of 
these shoulder single-DoF tasks is a condition for regaining proper arm function. 
The choice of single-DoF exercises was a deliberate design choice for clinical 
evaluation of the robot. In neurodevelopmental approaches in physiotherapy, it is 
known that, particularly in severe cases, the best therapy choices in order to induce 
physiological reorganization after brain injury (true recovery) are the ones that 
patients can control actively, and are challenging enough. The aim is to avoid the 
adoption of compensatory motor strategies and shoulder pain with tasks that are too 
demanding to accomplish, due to the reduced functional ability [40], [63]. This choice 
had potential because we could involve a significant number of patients, including 
those more severely affected.  
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Additionally, single-DoF exercises were more suitable for EMG-driven control with 
just one triggering muscle per task (Table 5). More complex movements, like the 
EIGHT tracking task, could have been confusing for patients, especially for those 
with more severely cognitive and concentration problems. Furthermore, tasks that 
are more complex require more advanced EMG-driven control algorithms relying on 
more muscles, a development that we consider as a future step. There was an 
attempt in this direction using pattern recognition for multi-DoF movements in the 
horizontal plane, but it was not practical [64]. Instead, it was suggested that a 
feedback of correct recruitment could be more practical.  
Since the subject-robot interaction is soft, the execution of the task is not 
stereotyped, i.e., the subject is not forced to repeat consistently and precisely the 
same movements. Instead, trial-to-trial movements will exhibit a certain level of 
variability, which is also the characteristic of the physiological human motor control. 
For maximum flexibility, it would be also possible to set only the initial and final 
positions, letting the subject freely choose the most convenient approach trajectory.  
This work has been also motivated by the need to close the loop in rehabilitation 
robotics. As demonstrated in EMG-driven robot tasks, the robot can be driven by the 
subject by capturing and processing the EMG activity to detect the motion intention. 
Through closed loop control, sensory motor integration is achieved, and it is 
hypothesized that this can promote the relearning of the movement. Only few 
compliant robots have been presented up to now implementing this concept [30], 
[38], but there were no robots specifically targeting the shoulder movement. 
The closed loop framework implemented in this study is flexible and can be used in 
many control scenarios, in addition to the context that has been shown here. The 
system allows for extensions and improvements to achieve an optimal outcome. For 
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example, in the present work with EMG-driven control, we did not adapt the support 
given to the patients. It may prove more beneficial to develop dynamic training 
protocols (e.g. “assist as needed” [65]) that allow subjects to gradually integrate 
active support of the limb with control of voluntary movement, in a manner similar to 
partial body weight support gait training [66]. Higher completion rate occurred 
because the challenge level was low for some patients of the mildly impairment 
group. We set forty repetitions as the maximum amount of repetitions to be 
performed in 20 min in order to compare the performance between patient groups. 
Future development should consider more challenging tasks and adaptation of 
threshold levels according to patient’s improvement due to therapy. 
By using multiple EMG channels for control, the system has the potential to be 
extended to actuate multiple shoulder DoFs sequentially or simultaneously, based on 
the detection of the patient’s intention [67]. The robot treatment was well accepted by 
all patients, this is a very important factor for the introduction of new rehabilitation 
technologies. 
3.2 Study 2: Efficacy of Torque Versus Myocontrol For Active, 
Robotic-Assisted Rehabilitation Of The Shoulder After Stroke: An 
Experimental Study Methods 
(This section is based on a published conference paper [2], “© [2015] IEEE. 
Reproduced with permission.  All rights reserved”; therefore text, results and 
graphics taken from this manuscript are not cited explicitly.  
3.2.1 Abstract 
Objective. This engineering study investigated whether torque or myoelectric control 
with EMG-thresholding is more practical during active, robotic-assisted therapy for 
the shoulder in a clinical setup. After showing the feasibility of using the RehaARM 
robot with closed-loop myoelectric control in study 1, the clinical and scientific 
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question whether myoelectric control has a more efficient applicability than 
torque/force control of the RehaARM robot for achieving more intensive upper limb 
therapy arose. Approach. 10 healthy subjects used the RehaArm robot in one daily 
one-hour session while 23 hemiparetic stroke patients used the robot in four daily 
one-hour sessions. During each session, subjects repeatedly performed basic 
movements of the shoulder in passive and active mode. The tasks to be executed 
were the same shoulder movements of the previous study 1. During the active mode 
(40 min in total), subjects were asked to complete 40 task repetitions (5 repetitions x 
4 single-DoF tasks x 2 directions) in 20 min for each modality, torque and 
myoelectric control. The number of movement repetitions achieved – task completion 
rate (CR) – was tracked for each control modality as well as subjective opinion about 
the ease of use of each modality after each daily session. Main Results. Using 
myoelectric and torque control, the group of healthy subjects executed 40 task 
repetitions in 20 min. The CR results over all days showed that the severe-to-
moderate impairment group (group A, n = 13) performed a significantly (p<0.001) 
higher number of task repetitions in the given time with myoelectric control in 
comparison to torque control. For the mild impairment group (group B, n = 10), the 
CR over all days was very similar for both control modalities, but their performance 
was more constant during the torque control (narrower IQ-range). Over time, group A 
performed tendentially better with both control modalities (higher median and Q1/Q3 
values) and there was a significant increase between CR at day 1 and day 4 for 
myoelectric (p<0.01) and torque control (p<0.05). Over time, group B also performed 
tendentially better with both control modalities (higher median and Q1/Q3 values, 
and narrower IQ-ranges), but there was not a significant difference between days. 
According to the questionnaires, the severe-to-moderate impairment group A 
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considered myoelectric control significantly easier to use than torque control at day 1 
and day 4 (p<0.05) while the mild impairment group B considered both control 
modalities similarly easy to use. Group A and group B activated their upper limb 
muscles similarly during myoelectric and torque control with respect to the healthy 
subjects group (no significant difference between EMG-S and TORQUE-S was 
found). Significance. Myoelectric control with simple EMG-thresholding was more 
practical than torque control for robotic-assisted therapy. The stroke patients 
reported on the perceived ease of use of the robot. For severely-to-moderately 
impaired patients this was greater with myoelectric control than with torque control 
and this was a motivating factor.  For mildly impaired patients this was the same for 
both types of control. There was a tendency to perform a higher number of task 
repetitions over time with both control modalities for both groups. This indicates that 
subjects learnt to adapt their motor control and use the robot with both control 
modalities, the myoelectric control being easier to use (higher CR and rating in 
questionnaires). The novel myoelectric control with simple-thresholding is practicable 
and neurophysiological because it can make a neurorehabilitation robot more 
responsive to subjects impairment (very small residual muscles signals can be 
reliably detected), and also allow the activation and coordination of muscles (muscle 
recruitment) of torque control. 
3.2.2 Methods 
In this study, 10 healthy volunteers (five male and five female subjects, 53.4 ± 18.1 
yrs) and 23 hemiparetic stroke patients (characteristics in Table 8) meeting study 
inclusion criteria were included. The inclusion and exclusion criteria were the same 
as for study 1. The IT-NIHSS score was also considered for assessing the 
maintenance of residual voluntary motor activation necessary for driving the robot 
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with myoelectric and torque control. The setting of the robot mechanically (arm 
length) and via software (max ROM) for adjusting the robot to the patient was done 
as in study 1.  In addition, the parameters for the closed-loop control (increment step 
𝑑𝑑𝐼𝐼𝐼𝐼𝑖𝑖 and path tolerance ∆�⃑ 𝑁𝑁𝐹𝐹𝐼𝐼ℎ for myoelectric and torque control in Figure 3(a) and 
(b), respectively) and maximum torque values were set to the same values as for 
study 1 (section 3.1.2.2). The EMG baseline and MVC value for determining the 
threshold value in myoelectric control were obtained individually at each trial and 
session as done in study 1 (section 3.1.2.2). 
The threshold for torque control was set individually by the physiotherapist at session 
1 and it was adjusted if necessary in the following sessions. The physiotherapist took 
care that the torque threshold was high enough to make the task challenging yet 
moderate in order to avoid strong fatigue. In addition, for patients with severe 
impairments the torque threshold was set to the minimum settable torque values 1 
Nm, 0.5 Nm and 1 Nm for DoF1, DoF2 and DoF3, respectively (section 2.2.4). This 
necessary setting for the correct function of the robot with torque control was a 
limiting factor for more severely impaired patients because they were often unable to 
exert enough residual force to surpass those torque values for some tasks, and 
therefore the robot was not activated. 
Patients executed the protocol in four daily sessions. One session lasted for 
approximately 1 h including patient preparation. When possible, the four visits were 
scheduled to occur consecutively within a one-week window. The protocol comprised 
the same 4-single-DoF tasks of study 1 (Table 5 in section 3.1.2.2). During each 
Table 8: patients characteristics for study 2 (n = 23)  
 Frequency median Q1-Q3 
Age  59.7 48.5-70.3 
Gender (M / F) 15/8   
Months since stroke  5 3.5-8.7 
FMA-UE (≤38 / >38) 13/10   
*Q1 and Q3 are the first and third Quartile. 
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daily session, the tasks were executed first passively by the robot (10 min), and 
afterwards subjects actively performed the tasks by using myoelectric (20 min) and 
then torque control (20 min), or viceversa (section 2.2.3 and section 2.2.4). The 
sequence of tasks and control modality were randomized for each session.  
During the passive mode, subjects learnt the movements and got comfortable with 
the robot. During the active modes, the subject had to actively and continuously drive 
the robot to complete the tasks in closed-loop using visual feedback of his force 
(torque control) or muscles signals (myoelectric control). The robot assisted the 
patient if the torque or EMG activity surpassed an individually settable torque/EMG 
threshold value for each movement.  
The instruction to control the robot with myoelectric control was the same as for 
study 1 (section 3.1.2.2). For torque control, the subject was also instructed to make 
an effort to move the robot towards the final position (𝑃𝑃�⃑𝐹𝐹𝐼𝐼𝐼𝐼𝐹𝐹𝐹𝐹) exerting residual force. 
The subject was then expected to monitor the visual feedback (Figure 2(c1)) and 
modulate the effort (torque) so that the light blue square (𝑇𝑇𝑗𝑗(𝑚𝑚)) moved out of the 
red zone in the direction of the green arrow, surpassing the torque threshold for the 
corresponding task (dashed black line,𝑇𝑇ℎ𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐸𝐸
𝑗𝑗 ), where 𝑗𝑗 = 1, . . . ,4  represents each 
task. As long as the subject maintained the light blue square above the torque 
threshold line, the robot assisted the movement towards the final position. Once 
activated, the robot moved at the same maximum speed (5 ̊/s) as for myoelectric 
control.  
The goal CR was 40 repetitions for each control modality during 20 min as in study 
1.  Healthy subjects were able to perform 40 repetitions with each modality in 20 min 
without strong fatigue, and this was therefore adopted as the desired goal for the 
patients due to limited therapy duration. The time out was also used as in study 1. 
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The total duration of a repetition, and therefore the number of completed exercises 
(CR) within the session time for EMG and torque control depended on how well the 
subject was able to maintain the muscle activation or torque above the threshold.  
After the first and fourth visit, two questions about the ease of use of each control 
modality were provided to the patients.  
The questions in the questionnaire were:  
1. How easy was to control the robot with torque (force of the arm)?  
2. How easy was to control the robot using muscle signals?  
Patients were provided with a visual analog scale displayed as a continuous line, 
ranging from 0 (difficult) to 10 cm (easy) to answer each of the questions. Each 
question was provided after each control modality. Then after completing the entire 
active part, an opportunity was given to review the answers. In this way, they 
completed both modalities and then confront them if they thought it was necessary. 
The EMG signals from the six triggering muscles were recorded at day 1, 2 and 3 for 
all patients. At day 4, the EMG signals from 16 channels were recorded from a 
subgroup of 20 patients, and just the six signals of the triggering muscles for the rest 
of the patients (n=3). For the healthy volunteers (n=10), the EMG signals from 16 
channels were recorded during the first only session (see section 2.2.2).  The 
recorded EMG signals at day 4 were processed in order to obtain the synergistic 
modules for each task (i.e. muscle activations per task), and then calculate the 
overall muscle activation similarity between the healthy subjects and stroke patients 
when using each control modality (see section 2.3.3).  
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3.2.3 Data Analysis 
As for study 1, the recorded EMG signals were manually inspected in order to 
remove those task repetitions with evident artifacts due to the electrode 
displacements or accidental contacts with the robotic parts. 
To assess the performance in completing the exercise, the CR was noted for each 
subject in each task and control modality per day, by counting the number of 
exercises in which the subjects reached the final position. This does not include the 
repetitions in which the time out period expired, and the robot therefore completed 
the movement on behalf of the passive subject.  
The patients were classified in two groups as in study 1. Therefore, there are three 
groups: the severe-to-moderate group A, the mild group B and the healthy subjects 
group. 
For each group, the overall task completion rate between torque and myoelectric 
control were statistically compared using the Wilcoxon Matched-Pairs Test (within 
group comparison). For each group, the results of task completion rate between 
days were statistically compared using the Friedmann test and the Dunn’s Post-hoc 
test. The results of the task completion rate of the patient groups were statistically 
compared using the Mann-Whitney U Test (between group analysis).  
The results of questionnaires about the ease of use of the control modalities of the 
patient groups were compared using the Kruskalwallis test followed by a Dunn’s 
post-hoc test (among group analysis). For each group, the ease of use of the control 
modalities at day 1 and day 4 and between day 1 and 4 were compared using the 
Wilcoxon Matched-Pairs Test (within group comparison). 
The overall muscle activation similarity in each control modality of the subject groups 
was compared using the Mann-Whitney U Test (between group analysis). The 
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overall muscle activation similarity between control modalities per patient group was 
compared using the Wilcoxon Matched-Pairs Test (within group comparison). 
As for study 1, nonparametric tests were used because the data distributions were 
not normal and the number of subjects was small for parametric tests, as determined 
by the Shapiro-Wilk Test. The statistical differences and normality rejections were 
tested at a significance level of p<0.05 as for study 1. The data and statistical 
differences are indicated in the text, boxplots and tables as for study 1. The 
statistical tests were done in the software IBM SPSS Statistics 22.  
 
Figure 11: Activation profile of six shoulder muscles, 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝟏𝟏  ,… 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝟔𝟔  (a), torque (b) and robot 
position (c) when the representative patient with a mild impairment was performing the 
exercise of internal/external rotation, DoF3 (d) using torque control. The 𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨𝑨  were the 
activation profiles determined and saved online during the session. The external rotation 
corresponded to a displacement of 46 degrees (from 37.6° to -8.4°) and the internal rotation 
corresponded to the reverse movement. The patient moved mostly along DoF3 (task direction), 
but the movement was not entirely planar, since there were some excursions along DoF1 and 
DoF2 (approx. 13° and 2.3°, respectively). The subject activated the robot when the torque 
value around DoF3 exceeded 1 Nm in the corresponding direction. The patient’s residual force 
was also strong enough to drive the robot progressively through the task without the robot’s 





The recorded signals for the movement along IE DoF for the representative patient 
with a mild impairment are illustrated in Figure 11 to demonstrate the operation of 
the robot. As long as the momentary torque threshold value around DoF3 in the 
direction of the of internal rotation (I) was over the threshold (1 Nm in Figure 11(b)), 
the robot actively assisted the patient until completing the task (I), i.e., DoF3 
changed from -8.4° to 37.6° (Figure 11 (c, d)). Similarly, while the torque level 
around DoF3 for of external rotation (E) exceeded the threshold (-1 Nm Figure 11 
(b)), the robot provided assistance during (E), i.e., the DoF3 changed from 37.6° 
 
Figure 12: Torque (b) when the representative patient with severe-to-moderate impairment (c) 
and with mild impairment were performing the exercise of internal/external rotation, DoF3 (b, d) 
using torque control. For the severe-to-moderate patient, the external rotation corresponded to 
a displacement of 46 degrees (from 6° to -40.8°) and the internal rotation corresponded to the 
reverse movement. The subject activated the robot when the torque value around DoF3 
exceeded 0.5 Nm for (a) and 1 Nm (b) in the corresponding direction. In (a), the patient’s 
residual force was not strong enough to drive the robot. Therefore, the passive mode was 
activated by the physiotherapist in order to avoid excessive fatigue. For (c), the patient’s 
residual force was strong enough to drive the robot progressively through the task without the 
robot’s passive assistance.  
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back to -8.4° (Figure 11 (c, d)). 
This patient also tended to move the robot around DoF1 while rotating the shoulder 
as with myoelectric control, but the excursions along this DoF were also limited 
(maximum restorative torques set to 20 Nm). Here again, this patient had no problem 
in applying residual force above the threshold level and completing the tasks without 
the robot assistance (Figure 11 (b)). 
Patients from group A had more often difficulties in applying sufficient residual force 
to surpass the minimum torque threshold of the robot. For example, a representative 
patient from group A tried to apply residual force around DoF3 during the internal 
and external rotation to surpass the threshold of 0.5 Nm for the I/E task (Figure 12 
(a)). The subject had difficulties in performing the task; however, the physiotherapist 
waited for 14 s and allowed the patient try to perform the task. As the patient did not 
 
Figure 13: Task completion rate (CR) for group A and group B using the EMG-driven control 
system over all days (left grey shaded area) and task completion rate (CR) for group A and 
group B using torque control over all days (right white area). The target CR per session for 
each control modality was 40 repetitions (5 repetitions x 4 single-DoF tasks x 2 directions). 
Group B executed a significantly higher number of repetitions over all days using myoelectric 




manage to apply enough force, the passive mode was activated by the 
physiotherapist in order to avoid excessive patient’s fatigue. In contrast, patients 
from group B had less difficulty in applying enough residual force and surpass the 
torque threshold to perform the tasks. For example, a representative subject from the 
mild patient group (Figure 12 (b)) applied enough force to surpass the torque 
threshold (1 Nm) and perform the I/E rotation task without the robot’s assistance. 
Summary results of the CR for the two patient groups over all days are plotted in 
Figure 13. All healthy subjects consistently reached the maximum number of 
repetitions (40) in the daily session with both control modalities, and the results for 
them are therefore not shown. The CR results over all days showed that the severe-
to-moderate impairment group (group A, n = 13) performed a significant (p<0.001) 
higher number of task repetitions in the given time with myoelectric control in 
comparison to torque control. The median CR over all days for myoelectric control 
was 18.5 task repetitions per daily session within 20 min with Q3 = 28 and Q1 = 12.5 
and the median CR over all days for torque control was 15 repetitions with Q3 = 22.8 
and Q1 = 10. For the mild impairment (group B, n = 10), the CR over all days was 
very similar for both control modalities, but their performance was more constant 
during the torque control (narrower IQ-range). For this group, the median CR over all 
days for myoelectric control was 40 task repetitions per daily session within 20 min 
with Q3 = 40 and Q1 = 33 and the median CR for torque control was 40 repetitions 
with Q3 = 40 and Q1 = 35.5.  
The mild-impairment group B performed significantly better than the severe-to-




Group A tended to increase the performance over time with myoelectric (left gray 
shaded area, Figure 14 (a)) and torque control (white area, Figure 14 (a)). From day 
1 to day 4, the median CR was 19, 18, 18, and 20 for myoelectric control and 10, 15, 
15, and 18 for torque control. There was a significant increase in performance at day 
4 in comparison to day 1 for myoelectric (p<0.01) and torque control (p<0.05). Group 
B exhibited a similar trend (Figure 14 (b)), increasing the median CR from 33 on day 
1 to 38.5 on day 2 and 40 on day 3 and 4 with myoelectric control and from 39.5 on 
day 1 to 40 on the remaining days with torque control. Group B used the robot very 
straightforward from the first day, and therefore the difference between days for 
group B was not significant. 
According to the questionnaire (Figure 15), at day 1 and day 4 group A (light gray 
boxplots) considered myoelectric control significantly easier to use in comparison to 
 
Figure 14: Completion rate (CR) for group A (a) and group B (b) using the EMG-driven (grey-
shaded areas) and torque control system (white areas) over consecutive days. The target CR 
per session for each control modality was 40 repetitions (5 repetitions x 4 single-DoF tasks x 2 
directions). There was a tendency towards a higher number of repetitions over time for both 
groups. Group A performed better with torque and myoelectric control at day 1 in comparison 





the torque control (p<0.05) while group B (white boxplots) and the healthy subjects 
group (dark grey boxplots, only did one daily session) considered both types of 
control similarly ease to use (no significant differences were found).  
At day 1 and day4, torque control was significantly easier to use for group B in 
comparison to group A (p<0.05). At day 1, group B perceived that myoelectric control 
was significantly easier to use in comparison to group A (p<0.05) while at day 4 both 
patient groups rated that myoelectric control was similarly ease to use (no significant 
difference was found). Healthy subjects used torque and myoelectric control 
significantly easier than group A at day 1 (p<0.05) while in comparison to day 4 just 
torque control was significantly easier to use for the healthy subjects group (p<0.05).  
Subjects thought that they were able to use the system better after four sessions 
 
Figure 15: Subjective opinion for group A (light gray boxplots), group B (white boxplots) and 
healthy subjects (dark grey boxplots) about the ease of use of each control modality after day 





(Figure 15). The median responses about ease of system’s use increased while the 
variability decreased at day 4 in comparison to day 1 (higher median, Q1 and Q3 
values and narrower IQ-ranges). However, no significant differences were found. 
According to the neurophysiological measurements, group A (light grey boxplots) 
and group B (white boxplots) and all patients together (dark grey boxplots) activated 
their muscles similarly using myoelectric (EMG-S) and torque control (TORQUE-S) 
with respect to the healthy subjects (no significant differences were found), Figure 
16.  This implies that stroke patients can recruit their muscles with myoelectric 
control (simple thresholding strategy) as they do it when applying residual force with 
torque control. Finally, group B activated their muscles using torque (p<0.01) and 
myoelectric control (p<0.001) more similarly to the healthy volunteers than group A 
did, as expected. 
 
Figure 16: Results of the muscle activation similarity over all tasks for group A (light gray 
boxplots), group B (white boxplots) and all patients (dark grey boxplots). The muscle 
activation of all tasks was obtained using the NNMF algorithm (see section 2.3.3) from 16 
surface EMG channels recorded session 4 for the patient groups and at the only daily 




The median reconstruction error of the muscles synergies for all tasks and directions 
was 77% for the healthy subjects group (third quartile Q3 = 81% and first quartile 
Q1= 70%) and 78% (Q3 = 84% and Q1 = 72%) for the stroke patients. 
The synergy set from the healthy subjects group can be visualized in Figure 17. 
Subjects recruited muscles very similarly during myoelectric and torque control (the 
 
Figure 17: Median synergy set for the healthy subject group (n=10). This is the reference of 
muscle recruitment for using the robot with myoelectric (upper two rows) and torque control 
(lower two rows). Healthy subjects recruited muscle patterns very similarly when using 




overall median of all tasks was 0.98). This indicates a high reliability of synergy 
extraction across tasks and control modalities for the healthy subjects groups. 
Therefore, the reference of muscle activations from the healthy subjects is a reliable 
reference for driving conclusions of the muscle recruitment patterns of patients and 
assessing the EMG-S and TORQUE-S of patients. 
In Figure 18, the synergy sets for a representative subject from group B and the 
 
Figure 18: Synergies for a representative patient from group B (green bars) and the median 
synergies of healthy subjects (black bars) for all single-DoF tasks and both control modalities 
EMG-driven control (upper two rows) and torque control (lower two rows). The EMG-S for this 
subject was 0.8 and the TORQUE-S for this subject was 0.85. The triceps brachii, lateral and 
medial head (←), was markedly more activated in the HORZ ABD task in comparison to the 
median activation of the same muscle for the healthy subjects. 
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synergy set from the healthy subjects group (n=10, reference muscle recruitment) for 
myoelectric and torque control can be visualized. The EMG-S and TORQUE-S for 
this representative patient were 0.8 and 0.85, respectively. The recruitment patterns 
for the tasks ABD/ADD and FE (flexion/extension) were more similar to the median 
muscle activation of the healthy subjects group (0.83 and 0.89 for myoelectric control 
and 0.89 and 0.91 for torque control, respectively) in comparison to the tasks HORZ 
ADD/ABD and I/E (0.76 and 0.71 for myoelectric control and 0.77 and 0.68 for torque 
control, respectively). For the task HORZ ABD, the triceps brachii, lateral and medial 
head (←), of the mildly impaired patient was markedly more activated than for the 
healthy subjects group. This muscle was probably more recruited due to 
compensatory strategies developed by the patient after the lesion. 
In contrast, the synergy sets for a representative subject from group A and the 
synergy set from the healthy subjects group (n=10, reference muscle activations) for 
myoelectric and torque control are shown in Figure 19. The similarity between a 
representative patient from group A and the healthy subjects group (reference 
muscle activations) was lower. The EMG-S and TORQUE-S for this representative 
patient were 0.7 and 0.69, respectively. For this patient with stronger muscle 
weakness, the attempt of voluntary movements resulted in activation of the abnormal 
“flexor synergies”. The presence of unwanted motor synergies after stroke has been 
described in the literature for over 30 years [68]. The severely impaired patient 
activated the biceps brachii, long head (∇), markedly stronger in comparison to the 
healthy subjects group in the tasks HORZ ABD, ABD, I and F during myoelectric 
control and HORZ ADD/ABD. ABD/ADD and F during torque control. For the tasks 
ABD/ADD and FE during torque and myoelectric control, the biceps brachii, short 
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head (→), was also strongly activated and the patient also compensated with the 
superior trapezius (←). 
3.2.5 Discussion 
This engineering study showed that the RehaARM with both control modalities 
permitted patients, even those severely affected, to understand how execute a task 
 
Figure 19: Synergies for a representative patient from group A (light blue bars) and the median 
synergies of the healthy subjects group (black bars) for all single-DoF tasks and both control 
modalities EMG-driven control (upper two rows) and torque control (lower two rows). The 
EMG-S for this subject was 0.7 and the TORQUE-S for this subject was 0.69. The biceps brachii 
long head (𝛁𝛁), was markedly more activated in five out of eight tasks of myoelectric control 
and in sex out of eight tasks of torque control in comparison to the median activation of the 
same muscle for the healthy subjects. For the tasks ABD/ADD and FLEX/EXT in torque and 
myoelectric control, the biceps brachii short head (→) and the superior trapezius (←) were 





of the protocol proposed in this study. The control of the robot for performing single-
DoF movements with muscles signals (myoelectric control) and residual force 
(torque control) made patients aware of the actions they have to take in order to start 
and continuously complete a task. For reaching this goal, the protocol included 
simpler, single-DoF shoulder tasks that are relevant for ADLs.  
The robot assisted the patients along those tasks, thereby limiting excursions along 
other DoFs (maximum torque setting). This facilitation contributed to the patients’ 
understanding and awareness of their motor control to perform a task with 
myoelectric and torque control. The elbow and the hand joint were fixed and this also 
facilitated the shoulder tasks. Even severely impaired patients were able to drive the 
robot into a movement (more easily with myoelectric than with torque control) while 
mild patients were able to actively perform brighter shoulder movements (with 
myoelectric and torque control). Therefore, the RehaARM system can be used for-
task specific training according to individual needs. 
The mild and severe-to-moderate patients were able to use both control modalities 
and performed better over the four consecutive days. The mild group had higher 
median and Q1 values over consecutive days with both control modalities. The 
severe-to-moderate group performed markedly better over consecutive days and 
significantly better at day 4 in comparison to day 1 with both control modalities 
(p<0.05). Physiotherapists could adjust the level of difficulty of the training to the 
patient's ability with both modalities to avoid compensation as much as possible. 
Therefore, the monotonic increase in the movement completion rate over multiple 
sessions reflects improvement in motor control. 
The mild patients performed similarly well (median CR ~ 40 over all days) with both 
control modalities to the healthy subjects group who all executed 40 task repetitions 
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in 20 min. The severe-to-moderate impairment group executed 18.5 and 15 (median) 
task repetitions over all days with myoelectric and torque control, respectively. That 
is approximately 46% and 38% of the performance of the healthy subjects (mild 
patients). This indicates that group A had more difficulty using torque control while 
group B used both modalities equally similar. In addition, according to the 
questionnaire, group A thought they were able to use myoelectric control more easily 
than torque control while group B and healthy subjects thought both modalities were 
similarly ease to use. 
Finally, stroke patients had similar synergistic motor control with modalities, 
myoelectric control and torque control. Even though, for myoelectric control (simple 
thresholding) just one triggering muscle was used per task, the synergistic activation 
of muscle groups was possible for executing the task. This indicates that for task-
specific training, the most important muscle can be chosen as triggering muscle for a 
certain task. This is a very important aspect for the usability of the presented 
myoelectric control algorithm for upper limb rehabilitation robots.  
3.3 Study 3: Myoelectric Robot-Assisted Rehabilitation for the Upper 
Limb after Stroke 
3.3.1 Abstract 
Objective. Robot-assisted therapy is a promising treatment providing high-dosage 
exercise therapy for improving motor function after stroke and providing likely 
benefits to generic ADLs. The novel EMG-driven RehaARM for the shoulder (active 
joint), its therapeutic concept and the results of a pilot clinical study conducted using 
this system are presented here. Approach. In this pilot study, 20 patients were 
eligible and each underwent 2 hours of daily therapy delivered 5 days per week, for 
17 days (~3.5 weeks). The 2 hours of therapy consisted of 1 hour of RehaARM 
robotic-assisted therapy and 1 hour of conventional therapy. The primary outcome 
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measures were the Fugl-Meyer Upper Extremity (FMA-UE) and Functional 
Independence Measure (FIM) scales. In an explorative part of this study, we used a 
historical comparison group (n = 19) from a prior clinical trial which had conventional 
therapy for 20 days (4 weeks), also for 2 hours daily. We compared the effectiveness 
of the treatment for the RehaARM group with that of the conventional therapy group. 
The sets of patients were comparable at baseline (age, sex, impairment level, etc.). 
The objective was to compare the treatments in terms of clinical effect. Main results. 
The treatment with the RehaARM significantly improved motor control (FMA-UE) and 
activity (FIM) scores. There was a statistically significant increase in FMA-UE and 
FIM scores following participation in the training program (p<0.001) with large effect 
sizes (r = 0.54 and 0.55, respectively). The median score of the FMA-UE increased 
for pre- to post-treatment (from 12.5 to 16.5) and the FIM also increased (from 98 to 
109). The scores for the conventional therapy also increased for pre- to post-
treatment (from 16 to 20 on the FMA-UE scale) and (from 97 to 107 on the FIM 
scale). There was no significant difference between the RehaARM and conventional 
therapy groups in the pre- and post-treatment increments, measured on the FMA-UE 
and FIM scales. Based on the FMA-UE scores, the sample sizes needed to 
determine the effectiveness of the treatment were similar for conventional therapy (n 
= 27, p<0.05; power = 0.8) and RehaARM therapy (n = 28, p<0.05; power = 0.8). 
There were no occurrences of serious adverse events related to the study. 
Significance. EMG-controlled robotic therapy for upper limb after stroke was carried 
out successfully with severely, moderately and mildly impaired hemiparetic stroke 
survivors. The results of this study indicate that training with an arm robot is safe and 
improves both body functions and independence in ADLs equally well as 
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conventional therapy alone at a comparable dose and dosage. This technique is 
promising as a new modality for active-assistive training after stroke. 
3.3.2 Methods 
3.3.2.1 Phase II Clinical Study with the RehaARM 
This study is a phase II clinical trial – also known as pilot trial in clinical research –
since it evaluated the efficacy and safety of the therapeutic treatment for the 
recovery of the upper limb after stroke with the RehaARM system. This study did 
neither have a control group nor a randomization. It should be used to optimize the 
design of a subsequent randomized phase III clinical trial – also known as pivotal 
trial – with one or more control groups and a larger sample size per group in order to 
compare the efficacy of robotic-assisted therapy plus conventional therapy with other 
treatments. For example, this study can guide the effective use of limited (financial 
and nonfinancial) resources essential for a successfully performed phase III trials 
[69]. 
The cohort of post-stroke patients considered for the study was selected from 
admissions to the Cerebrovascular Disease Unit of the Fondazione Ospedale San 
Camillo. Within this cohort of patients, those suffering from hemiparesis due to a first 
stroke in the region of the middle cerebral artery (MCA), anterior cerebral artery 
(ACA) and posterior cerebral artery (PCA) were screened for this study. CT/MRI 
scan indicated various combinations of brain lesions, i.e. large damage involving 
most of the vascular territory of the MCA, PCA or ACA or more discrete lesions of 
the cortical and/or subcortical areas supplied by branches of these arteries. This 
study included hemorrhagic and ischemic (cerebral infarction) stroke patients and 
one case of subarachnoid hemorrhage. Moreover, the patients included in the study 
had a Motor Arm sub-score between 1 and 3 on the Italian version of the National 
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Institutes of Health Stroke Scale (It-NIHSS) [70]. The inclusion and exclusion criteria 
were the same as for study 1 and 2 (see section 3.1.2.2). In addition, the patients 
were further divided in subgroups based on: (1) the baseline severity of motor 
impairment detected with the FMA-UE scale, similarly as for study 1 and 2 (group A 
is severe-to-moderate and group B is mild; see section 3.1.2.2); (2) the duration of 
stroke to rehabilitation interval, SRI (between 1 and 3 months, between 4 and 12 
months, exceeding 12 months); and (3) type of stroke and cerebral infarction. The 
types of stroke were ischemic stroke, intracerebral hemorrhage (ICH) and 
subarachnoid hemorrhage (SAH). The types of cerebral infarction were classified 
according to the Oxford Community Stroke Project classification (OCSP, also known 
as the Bamford or Oxford classification) using CT7 and MRI8. This classification 
groups types of cerebral infarction primarily based on clinical symptoms. In this 
study, there were patients with total anterior cerebral infarct (TACI), partial anterior 
circulation infarct (PACI) and posterior circulation infarct (POCI). There were no 
lacunar infarct (LACI) patients. LACI patients present a pure motor stroke, pure 
sensory stroke or ataxic hemiparesis. 
TACI refers to when a large cortical stroke occurred in both the deep and superficial 
areas of the MCA/ACA. TACI is diagnosed based on the following three symptoms: 
(1) homonymous hemianopia; (2) ipsilateral motor and sensory deficits, in which at 
least two out of three areas of the face, arms and legs are affected; (3) higher 
cerebral dysfunction (e.g. dysphasia, visuospatial disorder, decreased levels of 
consciousness). The volume of the infarct in patients with the complete clinical 
                                            
 
7 Computer tomography 
8 Magnetic resonance imaging 
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syndrome is significantly greater than that in patients with more restricted deficits 
(i.e., LACI or PACI) [71].  
The PACI group consists of cerebral infarcts affecting more restricted areas, relative 
to TACI, of the MCA/ACA area. They are caused by the occlusion of the upper 
division of the MCA in case there are no visual field deficits or of the lower division in 
case of minor motor/sensory deficits. Patients show two of the three syndromes of 
TACI, higher cerebral dysfunction alone, or a motor/sensory deficit less severe than 
those classified as LACI (e.g. confined to one limb, or to face and hand but not to the 
whole arm) [71]. 
POCI is a group of cerebral infarction associated with the brainstem, cerebellum, and 
occipital lobes. The symptoms presented by patients in this group are the following: 
"ipsilateral cranial nerve palsy with contralateral motor and/or sensory deficit; 
bilateral motor and/or sensory deficit; disorder of conjugate eye movement; 
cerebellar dysfunction without ipsilateral long-tract deficit (i.e., ataxic hemiparesis); or 
isolated homonymous visual field defect" (page 1522 in [71]). 
The TACI group has a negligible chance of good functional outcome and mortality is 
high and that POCI has the best chance of good functional outcome [71]. For the 
PACI group, no information regarding this improvement chance was found. 
This study is registered with ClinicalTrials.gov, identifier: NCT02321254. Twenty out 
of the twenty four enrolled patients (characteristics in Table 9) completed the 
rehabilitation program. Most of the recruited patients were severe-to-moderate in a 
subacute phase and suffered a cerebral infarct (Table 9). The patients underwent 
two hours of daily therapy for 17 days (approx. 3.5 weeks). The two-hour daily 
therapy consisted of one hour of RehaARM robotic-assisted therapy and one hour of 
conventional therapy. The daily therapy was provided on continuous days when 
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possible. In case of missed sessions, they were rescheduled the next day, in order to 
complete the full assigned rehabilitation program of 17 days of therapy. Up to three 
continuously missed sessions could be rescheduled. The minimum time for each 
session of conventional or robotic therapy (excluding time for preparation, 
diagnostics, and documentation) was 50 min. Patient preparation for the robotic 
therapy took approx.  5-10 min. Four subjects withdrew from the study because of 
scheduling conflicts. 
The conventional therapy was delivered as in regular rehabilitation, as was done for 
the historical conventional therapy group (see section 3.3.2.2). The RehaARM 
therapy involved performing single-DoF shoulder tasks (same tasks as in study 1 
and 2, section 3.1.2.2) for a period of one hour with the robot's assistance. The 
therapist was present at every session for the entire duration, as in a standard one-
to-one setting. The therapist's role was to manage the robot interface to adapt it to 
the current patient’s physical condition and to guide the patient with verbal 
instructions in case difficulties arose during the execution of the exercises. 
The Fugl-Meyer upper extremity (FMA-UE) and the Functional Independence 
Measure (FIM) scales were chosen as outcome measures for the upper limb motor 
Table 9: patients characteristics of the RehaARM group for study 3 (n=20) 
Patients   





Upper limb motor impairment Severe-to-moderate, group A (FMA-UE≤38) 14(70%) 
 
 Mild, group B (FMA-UE>38) 6(30%) 
 
SRI (months) median(Q3;Q1) 5.5(8.6;3.1) 
 
 ≤ 3 months 4(20%) 
 
 3<months<12 13(65%) 
 
 ≥12 months 3(15%) 
 
Stroke classification Ischemic 13(65%) 
 
 ICH 6(30%) 
 
 SAH 1(5%) 




function and the independence in ADLs, respectively. In addition to the primary 
outcomes, secondary outcome measurements were taken on a set of clinical scales 
and kinematic and novel neurophysiological scales (see section 2.3). 
The interventions were carried out by two therapists and baseline and post-treatment 
assessments were carried out by a different therapist.  The baseline assessment 
was carried out before the start of the treatment (session 1) and the post-treatment 
assessment was carried out after session 17. The baseline and post-treatment 
assessments included all clinical assessments (see section 2.3.1) and the kinematic 
measures (see section 2.3.2). The EMG measurements of 16 upper limb muscles 
were carried out at session one and session 17 in order to obtain the 
neurophysiological assessment at baseline and post-treatment (see section 2.3.3). 
3.3.2.2 Comparison of the RehaARM therapy with a Historical Conventional 
Therapy (CVT) group 
The historical CVT group (n = 19) was obtained from the database of Fondazione 
Ospedale San Camillo. The dataset was constructed from 2003 to 2012 for research 
purposes. It includes patients who suffered from a first-ever supratentorial stroke 
(ischemic and/or hemorrhagic) in the right and left hemisphere. The baseline 
characteristics of these patients (sex, age, impairment level, etc.) were comparable 
to the baseline characteristics of the RehaARM group (see section 3.3.4.2). The 
patients in this comparison group underwent conventional therapy for 20 sessions (4 
weeks), two hours daily. The interventions were planed continuously if possible and 
missed sessions were rescheduled to the next day.  
The conventional therapy program had common rehabilitation treatment given to 
patients after stroke in inpatient care. The techniques for restoring upper limb and 
lower limb motor functions were based on the Bobath principles [40], [72]. The 
upper-limb therapy included mobilization, motor tasks of increasing difficulty without 
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and with postural control depending on residual motor function, games, activities of 
daily living, or any combination of the four. The amount of upper-limb and lower limb 
therapy was tailored to the patient’s needs and goals. 
A subgroup of 19 out of 20 subjects from the RehaARM therapy group were selected 
in order to assess whether the treatment with the RehaARM reduces motor 
impairment and improves ability more effectively than conventional therapy does. 
The subject from the RehaARM therapy group with SAH was excluded since the 
conventional therapy group did not include SAH patients. 
In this study, the true difference in effectiveness between the RehaARM robotic-
assisted therapy and conventional therapy cannot be deduced. Our comparison is 
solely explorative. By using historical comparison groups in clinical trials differences 
in concomitant factors could bias outcomes. However, we strived to minimize 
phenotype variability and baseline factors (age, sex, impairment level, etc.) were 
comparable between the groups. Therefore, we believe we have sufficiently reduced 
potential biases to draw reliable conclusions.  
3.3.3 Data Analysis 
Differences in demographic and clinical characteristics between the CVT and the 
RehaARM groups at baseline were analyzed using the χ2 test, whereas median age 
differences were analyzed with a Wilcoxon matched-pairs test. Wilcoxon and Mann–
Whitney U tests were used to study the outcome differences within and between 
CVT and RehaARM treatment groups, respectively. The effect sizes were calculated 
based on the Wilcoxon matched-pairs test. Effect sizes ≥0.5 are considered strong, 
0.3≤effect sizes<0.5 are considered medium and 0.1≤effect sizes<0.3 are 
considered small [73], [74].  
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The required sample sizes for the CVT and the RehaARM group was calculated as 
described by Rosner [75] and using the software G*Power Statistical Power 
Analyses for Windows9 assuming a normal parent distribution and using a two-sided 
Wilcoxon matched-pairs test. The alpha level (p-value) was set to 0.05 and the beta 
level was set to 0.2 in order to have a statistical power of 80% for the sample 
calculation. 
As for study 1 and 2, the recorded EMG signals were manually inspected to remove 
the task repetitions with evident artifacts due to electrode displacements or 
accidental contacts with the robotic parts. The maximum values of the activation 
profiles for the triggering and scapular muscles (𝑚𝑚𝑠𝑠𝑚𝑚�𝐴𝐴𝐸𝐸𝐸𝐸𝐸𝐸𝑘𝑘 �) for each task and 
subject group were calculated as the median of the maximum activation values for 
each trial as in study 1 (see also section 3.1.3.2). The correlations between the 
neurophysiological and clinical measures were calculated using the Pearson’s 
correlation. 
As for the previous studies, nonparametric tests were used because the data 
distributions were not normal and the number of subjects was small for parametric 
tests, as determined by the Shapiro-Wilk Test. The statistical differences, normality 
rejections and correlations were tested at a significance level of p<0.05. The data 
and statistical differences are indicated in the text, boxplots and tables as for the 
previous studies (see also section 3.1.3.2).  The statistical tests were done in the 
software IBM SPSS Statistics 22.  
                                            
 
9 http://www.gpower.hhu.de/  from the Düsseldorf University 
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3.3.4 Results  
3.3.4.1 Phase II Clinical Study with the RehaARM 
The results for all patients indicated that motor function significantly improved after 
treatment. There was a significant increase (p<0.001) of the FMA-UE score with a 
large effect size (r = 0.54). The median score increased for pre- to post-treatment 
(from 12.5 to 16.5). See Table 10, overall results. 
The motor function significantly improved for group A (p<0.01) and group B (p<0.05) 
after therapy with a large effect size (r = 0.53 and 0.59, respectively). The median 
score on the FMA-UE increased pre- to post-treatment (from 9.5 to 12) for group A 
and from 50.5 to 60 for group B. See Table 10, motor impairment. 
Subacute patients showed a significant improvement (p<0.01) after treatment with a 
large effect size (r = 0.52). The median score on the FMA-UE increased pre- to 
post-treatment (from 11 to 17).  There was no significant increase for the acute and 
chronic group because the sample size was too small, resulting in a low statistical 
power. The median score on the FMA-UE increased pre- to post-treatment both for 
the acute group (from 31.5 to 36.5) and for the chronic group (from 12 to 16). See 
Table 10: effect of therapy on the Fugl-Meyer Upper Extremity Scale (FMA-UE) 










 20 12.5 (41.3;8.3) 16.5 (45.5;10.3)*** 0.54 7(35%) 
Motor impairment Group A 
 
14 9.5(13.8;7.8) 12(17.5;9)** 0.53 3(21%) 
 Group B 
 
6 50.5(55.8;41.3) 60(62;43.5)* 0.59 4(67%) 
Stroke to Rehabilitation Interval 
(SRI) 
≤ 3 months 
 
4 31.5(56;9.3) 36.5(61.5;13) / 2(50%) 
 3<months<12 
 
13 11(40.5;7.5) 17(45;9)** 0.52 5(38%) 
 ≥12 months 
 
3 12(16;9) 16(19;11) / 0 
Stroke classification       Ischemic  TACI 
 
5 12(27.5;6.5) 13(29;8) / 0 
 PACI 
 
6 13(52;8.8) 16(60.5;10.5)* 0.58 2(33%) 
 POCI 
 
2 24(27.8;8.3) 31.5(34.5;12.8) / 2(100%) 
  Hemorrhagic ICH 6 17(52;7) 18(60.5;8.8)* 0.58 
 
2(33%) 
 SAH 1 39 44 / 1(100%) 
Frequencies for MCID are expressed as numbers and percentages; 
“*”,“**” and “***” within group analysis (Wilcoxon Matched-Pairs Test). 
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Table 10, SRI. 
The PACI group showed a significant improvement (p<0.05) after treatment with a 
large effect size (r = 0.58). The median score on the FMA-UE increased for pre- to 
post-treatment (from 13 to 16). The median FMA-UE score did not significantly 
change for the TACI group. For the POCI group, due to the small sample size (n=2), 
and subsequently low statistical power, no statistics are reported. The median score 
on the FMA-UE increased pre- to post-treatment for the TACI group (from 12 to 13) 
and for the POCI group (from 24 to 31). See Table 10, ischemic stroke. 
The ICH group showed a significant improvement (p<0.05) after treatment with a 
large effect size (r = 0.58). The median score on the FMA-UE increased pre- to post-
treatment (from 17 to 18). For the patient with the SAH, the score increased by five 
points (from 39 to 44). See Table 10, hemorrhagic stroke. 
There were 7 out of the 20 patients (35%) that gained at least 5 points on the FMA-
UE scale. In group A 3 of the 14 patients (21%) and in group B 4 of the 6 (67%) 
patients also achieved at least 5 points. About a third of the patients with ischemic 
(4/13) and ICH (2/6) also achieved at least five points.  
Table 11: effect of therapy on the Functional Independence Measure (FIM) 








 20 98(110;81.3) 109(117.8;94)*** 0.55 3(15%) 
Motor impairment Group A 
 
14 98.5(108.5;81) 104(115.3;91.3)** 0.58 1(1%) 
 Group B 
 
6 95.5(112.5;78) 113.5(121.3;97.5) / 2(33%) 
Stroke to Rehabilitation Interval ≤ 3 months 
 
4 87(97.3;70) 97.5(116.8;86.5) / 1(25%) 
 3<months<12 
 
13 98(108;81) 107(116.5;88.5)** 0.55 2(15%) 
 ≥12 months 3 113(119;107) 114(119;111) / 0 
       
Stroke classification       Ischemic TACI 
 
5 99(109;67) 101(112;83)* 0.65 1(20%) 
 PACI 
 
6 94(114;78) 105(120.5;91.5)* 0.58 1(17%) 
 POCI 
 
2 93(78.8;60.8) 106.5(89.3;70.5) / 0 
Hemorrhagic ICH 6 101(117.5;87.8) 112.5(119.5;99.5) / 1(17%) 
       
 SAH 1 98 102 / 0 
Frequencies for MCID are expressed as numbers and percentages; 




The results for all patients showed that the score in the activity scale (FIM) 
significantly improved after the therapy program. There was a significant increase 
(p<0.001) with a large effect size (r = 0.55). The median score increased for pre- to 
post-treatment (from 98 to 109). See Table 11, overall results. 
The severe group A showed a significant increase (p<0.01) after treatment with a 
large effect size (r = 0.58). The median score increased for pre- to post-treatment 
(from 98.5 to 104). For group B, the median showed a non-significant increase (from 
95.5 to 113.5). See Table 11, motor impairment. 
The TACI and PACI group showed a significant increase (p<0.05) with large effect 
sizes (r = 0.65 and 0.58, respectively). The median score increased pre- to post-
treatment for the TACI group (from 99 to 101) and for the PACI group (from 94 to 
105; See Table X, stroke classification). For the POCI group due to the small sample 
size (n=2) and low statistical power, no statistics are reported. The median score 
increased from 93 to 106.5. See Table 11, ischemic stroke. 
The FIM scores showed a non-significant improvement for the ICH group and the 
SAH patient after treatment. The median scores increased pre- to post-treatment for 







Motor FIM (77) 55.5 (66.8;40.8) 63.5 (71.5;48.5)** 0.49 
FM (152) 90(108.5;77.5) 91(124.8;86)*** 0.54 
MAS (20) 1(4.8;0) 2(4;0) / 
NHPT (9) 0(0;0) 0(1;0) / 
RPS (36) 6(27;0.3) 11(29.3;3)** 0.44 
Shoulder_ABD (°) 18(52.5;6) 37(69.3;13)*** 0.53 
Shoulder_FLEX (°) 24(73.5;5.5) 28.5(98;12)* 0.37 
Elbow_FLEX (°) 69(141;15) 97(158;20)* 0.4 




ICH (from 101 to 112.5) and for the SAH subject (from 98 to 102). See Table 11, 
Hemorrhagic stroke. 
On the FIM scale 3 of the 20 patients (15%) achieved gains of at least 22 points. In 
group A just 1 of the 14 patients (8%) and in group B 2 of the 6 patients (33%) 
achieved at least 22 points. For ischemic stroke, 2 of the 13 patients (15%) and for 
ICH 1 of the 6 patients (17%) also achieved at least 22 points.  
For the secondary measurements (Table 12), motor FIM, FM, RPS and all kinematic 
measures (shoulder_ABD, shoulder_FLEX and elbow_FLEX) showed significant 
improvement post-treatment (p<0.05). Non-significant results were obtained on the 
activity scale NHPT for finger dexterity. This result is unsurprising considering the 
upper limb was treated proximally. Non-significant change was found in the 
impairment scale MAS. This indicates that there is no evidence that spasticity 
increased after the treatment which is a very positive result.  
There was no significant difference between EMG-S and TORQUE-S at baseline. 
EMG-S significantly improved (p<0.0001) with a large effect size (r = 0.62) after 
treatment. The median score increased pre- to post-treatment (from 0.62 to 0.69). 
Group A (p<0.001) and group B (p<0.05) showed a significant improvement after 
treatment with a large (r = 0.52) and medium effect (r = 0.35) size, respectively. The 
median score increased pre- to post-treatment for group A (from 0.54 to 0.63) and 
for group B (from 0.74 to 0.80).  See Table 13. 
Table 13 effect of therapy on the neurophysiological measurements 








 20 0.62 (0.75;0.51) 0.69 (0.8;0.61)**** 0.62 
 Motor impairment Group A 
 
14 0.54(0.66;0.5) 0.63(0.75;0.57)*** 0.52 
  Group B 
 
6 0.74(0.8;0.72) 0.80(0.86;0.77)* 0.35 
TORQUE-S Overall 
 
 20 0.62 (0.72;0.54) 0.68 (0.76;0.57) 0.31 
 Motor impairment Group A 
 
14 0.57(0.66;0.51) 0.61(0.72;0.55) 0.29 
  Group B 
 
6 0.72(0.79;0.68) 0.76(0.79;0.70) 0.12 




The results for all patients showed that TORQUE-S also improved after the therapy 
 
Figure 20: Raw EMG signals (a) and synergies (b) for the task ABD/ADD in the initial 
assessment (upper grey-shaded area) of a representative patient from the severe-to-moderate 
group A and raw EMG signals (c) and synergies (d) for the same task in the final assessment 
(bottom white area) of the same patient. The signals from 15 muscles and the corresponding 
synergy modules are displayed. The muscle 8 (trapezius) was excluded because of strong 
artifacts. The raw EMG signals and the synergies show an improvement after treatment. In the 
final assessment, there was activity in the teres (↓) and medium deltoids (𝛁𝛁) in contrast to the 
initial assessment. The black synergy modules in (b) and (d) represent the median muscle 
activity of the healthy subjects group and the light blue synergy modules represent the muscle 





program. The median score increased non-significantly pre- to post-treatment (from 
0.62 to 0.68). The effect size of the treatment was medium (r=0.31). TORQUE-S 
improved non-significantly for both groups after the therapy program. See Table 13. 
The neurophysiological measurements EMG-S and TORQUE-S significantly 
correlated (p<0.01) with the FMA-UE scale in the initial (0.73 and 0.69, respectively) 
and final assessment (0.83 and 0.69, respectively). Contrastingly, no significant 
correlations were found between the neurophysiological scales and the FIM scale, 
Table 14. 
The raw EMG signals for a representative subject from group A before and after the 
treatment are visualized in Figure 20. During the initial neurophysiological 
assessment (at day one, grey-shaded area in Figure 20), the patient could not 
execute the task ABD/ADD because the required muscles teres (for ADD) and 
medium deltoids (for ABD) were inactive. Nevertheless, the therapist allowed the 
patient to try to execute the task with guidance. As there was not activation, the 
therapist activated the passive mode and asked the patient to follow the movement 
with effort. During the final assessment (at day 17; white area in Figure 20), the 
patient was able to execute the task with complete autonomy and there was 
activation in the teres (↓) and the medium deltoids (∇) (Figure 20 (b)). The after 
treatment synergies in myoelectric control for the task ABD/ADD became present 
and more similar to the median synergies of the healthy subjects group. The median 
similarity for the task ABD/ADD improved pre- to post-treatment (from 0.26 to 0.43). 
However, the synergies were still markedly different from the synergies of the 
healthy subjects group. 
The maximum activation of the rotator cuff muscles significantly improved for the 
severe-to-moderate group A after treatment. The maximum activation value of the 
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teres improved (p<0.05) for the ADD and the EXT, similarly the maximum value of 
activation of the infraspinatus improved (p<0.01) for the FLEX task.  
No serious side effects occurred in this study. One patient from group B reported 
mild shoulder pain. Therefore, therapy was interrupted for three sessions and then 
resumed by narrowing the ROM without further adverse events. No further adverse 
events were reported. 
3.3.4.2 Comparison of the RehaARM therapy with a Historical Conventional 
Therapy group (CVT) 
At baseline (Table 15), the characteristics of the RehaARM therapy group and the 
CVT group were comparable on the variables: age, sex, SRI, stroke type and FMA-
UE scores.  
Results on FMA-UE (Table 15) showed no significant difference in the score change 
after treatment between conventional therapy and RehaARM therapy. Conventional 
therapy and RehaARM had strong effect sizes (r = 0.58 and 0.57, respectively). As a 
result, the samples sizes needed to show the effectiveness of the treatment were 
similar for conventional therapy (n = 27; power = 0.8) and RehaARM therapy (n = 28; 
power = 0.8). 
Results on FIM (Table 15) showed no significant difference in the score change after 
treatment between conventional therapy and RehaARM therapy. Conventional 
therapy and RehaARM had strong effect sizes (r = 0. 6 and 0.57, respectively). In 
addition, the samples sizes needed to show treatment effectiveness were similar for 
Table 14: correlation between neurophysiological and clinical measures 
Assessment time Variable Pearson correlation 
Initial EMG-S and FMA-UE  0.734** 
 EMG-S and FIM 0.079 
 TORQUE-S and FMA-UE  0.694** 
 TORQUE-S and FIM -0.074 
final EMG-S and FMA-UE  0.83** 
 EMG-S and FIM 0.054 
 TORQUE-S and FMA-UE  0.693** 




conventional therapy (n = 25; power = 0.8) and RehaARM therapy (n = 28; power = 
0.8).   
Similar numbers of patients in both groups achieved the clinically meaningful change 
(MCID) in the FMA-UE score: 8 of the 19 patients (42%) assigned to the CVT and 6 
of the 19 patients (32%) assigned to RehaARM therapy improved by at least five 
points. Furthermore, similar numbers of patients in both groups achieved the 
clinically meaningful change in the FIM score: 1 of the 19 patients (5%) assigned to 
the RehaARM therapy and 3 of the 19 patients (16%) assigned to RehaARM therapy 
improved by at least 22 points, Table 15. 
3.3.5 Discussion 
The results of this study agree with existing evidence that arm robotic-assisted 
therapy improves body functions and may be beneficial for improving ADLs [5]. Of 
the patients treated with the RehaARM, 35% achieved the clinically meaningful 
change in FMA-UE score and the effect size of the therapy was strong (r = 0.54; 
Table 15 effect of therapy on the FMA-UE  and FIM scale in the RehaARM and CVT group  
  Conv Therapy (n=19) RehaARM (n=19) p 
Age  62.4(66.4;53.1) 52(68.3;44) 
 
0.36 a 
Sex (M/F)  14/5(74% / 26%) 12/7(63% / 37%) 0.49 b 
 
SRI median(Q3;Q1) 5.1(10.4;3) 5.9(8.7;3.1) 0.8 b 
 n; ≤ 3 months 5(26%) 4(21)b  
 n; 3<months<12 10(53%) 12(63)  
 n; ≥12 months 4(21%) 3(16) 
 
 
Stroke type Ischemic 13(68%) 13(68%) 1 b 
  6(32%) 6(32%)  
     
FMAPRE-TREATMENT median(Q3;Q1) 16(44;6) 12(42;8) 1 b 
 n; <= 38 14(74%) 14(74)  
 n; > 38 5(26%) 5(26) 
 
 
Acc. to FMA Median ∆(Post-Pre) 4 3 0.79 a 
 Effect size r; p-value 0.58; p<0.001 c 0.57 ; p<0.001 c  
 Sample size (power=0.8) 27 28  
     
Acc. to FIM Median ∆(Post-Pre) 5 4 0.8 a 
 Effect size r; p-value 0.6; p<0.001 c 0.57 ; p<0.001 c  
 Sample size (power=0.8) 25 28  
     
N over MCID FMA-UE 8(47%) 6(32%)  
 FIM 1(5%) 3(16%)  
Frequencies are expressed as numbers and percentages. Age, SRI and FMAPRE-TREATMENT are presented as median(Q3;Q1) 
a: Mann-Whitney Test 
b: χ2 test 




p<0.001). The FIM score also increased significantly after treatment, with a strong 
effect size (r = 0.55; p<0.001). However, the 3 out of 20 (15%) patients reaching the 
MCID was lower than for FMA-UE. 
According to the FMA-UE scale, there is strong evidence that the RehaARM 
treatment was more effective for the subacute and mild population as well as the 
PACI group, in terms of large effect sizes and motor function improvements above 
the established MCID. The FMA-UE score increased for the POCI group above the 
MCID, but the sample size was too low (n=2) to be able to draw any conclusions for 
this group.  
According to the FIM scale, there is strong statistical evidence that the treatment was 
more effective for severe and subacute patients, TACI and PACI group in terms of 
large effect sizes.  
Of severe-to-moderate patients 3 out of 14 (21%) reached the MCID on the FMA-UE 
scale. Of mild patients a higher percentage, 4 out of 6 patients (67%), reached the 
MCID. A higher training dose and dosage of RehaARM robotic-assisted therapy may 
be necessary for more severely impaired patients. Future clinical trials should aim at 
determining these quantities. It has been suggested that durable and intense robotic 
therapy (5 days a week of 5 h/day for 12 weeks) leads to an incremental progression 
and seems to be necessary for patients with severe-to-moderate impairment as 
shown in the study by Daly and colleagues using the Inmotion shoulder-Elbow robot 
(the 12 involved severe-to-moderate patients were also chronic, [19]). 
The effect of the treatment on EMG-S was larger than on TORQUE-S for all patients 
and subgroups (group A and group B) likely due to subjects adapting their motor 
control to and training with myoelectric control. Additionally, myoelectric control 
allowed subjects to train with less physical and mental fatigue (larger CR and more 
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positive ratings in questionnaires for myoelectric than torque control; see section 
3.2.4). Nonetheless, the neurological results, based on torque and myoelectric 
control, revealed muscle activation improvement after treatment. 
Correlation analysis revealed that the neurophysiological measures have a 
significant relationship with the FMA-UE, but not the FIM scale. This strong, positive 
correlation is a very encouraging result. The FMA-UE is grounded in well-defined, 
observable stages of motor recovery and is taken as the gold standard against which 
the validity of other scales is assessed [45]. EMG-S and TORQUE-S can be used to 
tailor a treatment and infer motor impairment changes. 
The improvement in strength of the rotator cuff muscles significantly increased for 
the severe-to-moderate group A for the tasks ADD and FE. This is a very important 
result given the 2:1 ratio scapulohumeral rhythm, i.e. the contribution of the scapula 
muscles to the arm movements (see also section 3.1.2.2).  For example, for 90° 
flexion, the scapular muscles become active and move in the setting phase, which is 
the preparatory phase which spans the first 30 degrees of the movement. 
No significant improvements were found for the trigger muscles for any of the 
groups. 
Therapists reported that observation of the EMG signals during training was very 
useful because observing the relative activation of muscles during task execution 
allowed them to instruct the patient better. The neurophysiological measures can be 
used to assess abnormal activation patterns and adjust the treatment according to 
individual needs.  
Training with the RehaARM robot combined with conventional therapy improved both 
motor function and independence in ADLs equally well as conventional therapy 
alone at a comparable dose and dosage. 
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There was no statistical difference between the RehaARM and CVT conditions 
according to the FMA-UE and FIM scores. Similar numbers of patients in both 
groups achieved the clinically meaningful change in FMA-UE and FIM scores. 
Results agree with the available clinical evidence that same dose-matched exercise 
with robots and conventional therapy are equally effective [8], [26], [34], [76]. 
Pilot clinical studies and systematic reviews have suggested that one advantage of 
robot-assisted therapies may be an increase in repetitions during arm training due to 
a greater motivation to train [17]. Our findings suggest that the increased number of 
repetitions with the robotic therapy in comparison to conventional therapy within a 
comparable unit of time did not improve the clinical outcomes. This does not rule out 
that performance may increase along with training time. The robot is capable of 
tracking these changes accurately. Furthermore, the conventional therapy group had 
20 sessions while the RehaARM therapy group had 17 sessions. The non-significant 
higher effect of conventional therapy alone – one point higher for both FMA-UE and 
FIM scales – demonstrates that these 3 additional sessions did not lead to better 
outcomes for the conventional therapy group. 
Robotic devices allow patients to train more independently since patients are 
engaged in a virtual stimulating environment performing functional tasks at their own 
pace ([17], [77]). The RehaARM robotic-assisted therapy also permitted patients to 
train more independently using the robot as a vehicle. Meanwhile, the 
physiotherapist was able to read and document on the computer the patient’s report 
while supervising the patient. Patients were especially motivated with the RehaARM 
therapy when they saw that the muscle activation surpassed the threshold more 
often with training. The RehaARM therapy allows patients with varying impairment 
levels to train shoulder movements safely and enjoyably.  
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The required patient preparation for the RehaARM therapy was short (approx. 5-10 
min). Therefore, this therapy can be used as an additional component within 
therapeutic concepts, such as in an efficiency-focused setting where one therapist 
treats two5 or more patients [19] or two therapists treat three or more patients with 
similar impairments. In this way, more high-intensive therapy can be offered with the 
same amount of personnel. Alternatively, robotic therapy can complement the upper 
limb therapy in a setting where conventional therapy is carried out by a 
physiotherapy or occupational therapist and the robotic therapy is performed by an 
apprentice of either field since the procedure to work with the robot can be simplified 
to a greater degree, compared with the procedures of conventional therapy. For 
example, on the first therapy day the therapist adjusts the initial robot settings and 
the therapy plan and the instructed apprentice executes the following therapy 
sessions. Supervision should be an important element in order for the apprentice to 
learn how to adjust the robot if needed. I have developed this upper limb training 
concept for the therapy assistants together with the head of occupational therapy at 
my current job in the Rehaklinik Zihlschlacht using the Armeo Spring from Hocoma. 
The dosage of upper limb therapy has been increased and we can welcome in the 
clinic young apprentices for their internship period. They learn about the use of 
robots in neurorehabilitation in combination with conventional therapy. The results 
are very positive so far. Furthermore, robotic therapy could be offered via 
telerehabilitation in a home environment for outpatients where the physiotherapist 
continuous offering therapy remotely to patients who are suitable for the intervention 
and were instructed on how to use the robot in the inpatient-period. This 
development has the potential of saving travelling time and incrementing the 
independent time of training. For the RehaARM therapy a patient’s relative can be 
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instructed on how to place the electrodes. As the myoelectric interface can be 
transferred to other robotic applications, the system and therefore the placing of the 
electrodes could be simplified (e.g. a portable system for the shoulder with less 
electrodes for assisting shoulder flexion and extension movements which are 
necessary for reaching tasks). 
Some limitations are present in the current study with the RehaARM. This trial is still 
small in sample size. Therefore, the sample sizes for the subgroups were insufficient 
to perform statistical tests in some cases – due to low power – and detect significant 
differences in the primary outcomes (e.g. the subacute, chronic POCI groups). 
Further clinical trials with the RehaARM therapy with myoelectric control should 
determine with sufficiently high statistical power to which extent various patient 
populations profit from the treatment. The results of this study can guide decisions 
for future research (e.g. as a basis for selection of sub-groups, and power and 
sample calculations). Another limitation is the inability of the system to adjust the 
assistance; therefore, arm strength training may have been restricted. Further 
development on the RehaARM system should aim to automatically adapt this 
parameter as subjects improve. Alternatively, this parameter could be adaptable 




Currently commercially available force sensors and robotic devices are unable to 
detect the forces/movements of many severely disabled patients. Many of them are 
still capable of generating residual voluntary EMG, which can be used as the control 
signal for the rehabilitation robot. This allows those patients to engage in early-stage 
user-driven rehabilitation training.  
Study 1 showed that myoelectric control of the RehaARM robot with thresholding, 
using multichannel bipolar EMG measurements and single-DoF shoulder tasks, was 
feasible in a clinical setting. Stroke patients with varying levels of motor impairment 
were able to use the system safely and without problems. That more severely 
impaired patients were able to use the system is particularly remarkable. As this 
means that robotic-assisted therapy becomes another viable treatment option for this 
stroke population.  
Study 2 demonstrated that patients are capable of controlling the RehaARM using 
interaction forces (torque control). However, the sensitivity and transparency – and 
by extension the robotic device's responsiveness – depend on the technical 
characteristics of the robotic device. Myoelectric signals are sensitive control inputs 
that are generated and measured independently of the robot. Study 2 showed that 
more severely impaired patients were able to control the assistive RehaARM system 
more easily via myoelectric signals than via torque control, i.e., with less physical 
and mental fatigue.  
Study 3 showed that the EMG-driven RehaARM in combination with conventional 
treatment offers an effective treatment alternative for upper limb therapy. Patients of 
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all levels of motor impairment engaged in the therapy and trained independently with 
the therapist’s guidance. Robotic systems, such as the RehaARM and associated 
therapeutic concept proposed in this PhD project, offer new possibilities for efficient 
therapy with a lower than one ratio of therapists to patients5. This could allow for the 
provision of more intensive therapy and reduction of healthcare costs. Furthermore, 
the presented neurophysiological and kinematic measurements complement the 
clinical measurements and can guide and support the physiotherapist in tailoring the 
therapy to the individual, assessing the level of improvement during therapy and 
adapting the therapy to that improvement. 
This project’s scientific and clinical outcomes are the foundation of the scientific 
achievements in robot-aided rehabilitation within the MYOSENS project. The 
Fondazione Ospedale San Camillo continues using the RehaARM robot with 
myoelectric control for upper limb treatment after stroke in its clinical routine. 
Furthermore, Hocoma10 and I are currently exploring the possibility of applying the 
findings of this PhD project into a commercially available robotic application. This 
underlines the continuing impact of the work presented on the field of robotic-
assisted therapies for upper limb recovery after stroke. This PhD project – through 
testing the efficacy of upper limb therapy after stroke in studies with stroke patients 
and a clinical trial – contribute to the advancement of robotic-assisted upper limb 
therapy.  
                                            
 
10 Hocoma is the global market leader for the development, manufacturing and marketing of robotic 
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